• Abbasi AM, Chester KA, MacPherson AJ, Boxer GM, Begent RH, Malcolm AD. Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas. J. Pathol. 168: 405-411 (1992).

• Abraham LJ, Leelayuwat C, Grimsley G, Degli-Esposti MA, Mann A, Zhang WJ, Christiansen FT, Dawkins RL. Sequence differences between HLA-B and TNF distinguish different MHC ancestral haplotypes. Tissue Antigens 39: 117-121 (1992).

• Adams DH, Mainolfi E, Burra P, Neuberger JM, Ayres R, Elias E, Rothlein R. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology 16: 810-814 (1992).

• Adler M, Bourgeois N, van de Stadt J, Gelin M. A Pugh score of 8 adequately selects patients with parenchymal cirrhosis for liver transplantation. Transpl. Int. 5 Suppl. 1: S175-S178 (1992).

• Aizawa K, Kawaguchi S, Doi M, Mizuno W, Uragami K, Oka T, Miyamoto H, Itoh H, Nishioka S. A case of primary intrahepatic sclerosing cholangitis (PISC) complicated with atypical biliary epithelial proliferation. Intern. Med. 31: 114-121 (1992). *

• Akahoshi K, Miyata Y, Hashimoto M, Koga S, Chijiiwa Y, Misawa T, Suematsu E, Nishimura J, Nawata H. A case of combined primary biliary cirrhosis, ulcerative colitis and chronic myelocytic leukemia. Gastroenterol. Jpn. 27: 252-257 (1992).

• Akpolat T, Koc Y, Yeniay I, Akpek G, Gullu I, Kansu E, Kiraz S, Ersoy F, Batman F, Kansu T, et al. Familial Behcet's disease. Eur. J. Med. 1: 391-395 (1992).

• Albani S, Roudier J. Molecular basis for the association between HLA DR4 and rheumatoid arthritis. From the shared epitope hypothesis to a peptidic model of rheumatoid arthritis. Clin. Biochem. 25: 209-212 (1992).

• Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol. Clin. North Am. 21: 643-658 (1992).

• Allgayer H, Hofer P, Schmidt M, Bohne P, Kruis W, Gugler R. Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem. Pharmacol. 43: 259-262 (1992).

• Amar A, Brautbar C, Goldin E, Sherman L, Barmeir S, Shouval D, Hansen JA, Smith AG. Serological and molecular analysis of HLA in Israeli primary sclerosing cholangitis patients. Eur. J. Immunogenet. 19: 295-302 (1992).

• Andersen KB, Nilsson A, Blomhoff HK, Oyen TB, Gabrielsen OS, Norum KR, Blomhoff R. Direct mobilization of retinol from hepatic perisinusoidal stellate cells to plasma. J. Biol. Chem. 267: 1340-1344 (1992). *

• Ashman RF, Schaffer FM, Kemp JD, Yokoyama WM, Zhu ZB, Cooper MD, Volanakis JE. Genetic and immunologic analysis of a family containing five patients with common-variable immune deficiency or selective IgA deficiency. J. Clin. Immunol. 12: 406-414 (1992).

• Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am. J. Gastroenterol. 87: 432-437 (1992).

• Babb RR. Chronic liver disease. The scope of causes and treatments. Postgrad. Med. 91: 89-96 (1992).

• Baccala R, Smith LR, Vestberg M, Peterson PA, Cole BC, Theofilopoulos AN. Mycoplasma arthritidis mitogen. V beta engaged in mice, rats, and humans, and requirement of HLA-DR alpha for presentation. Arthritis Rheum. 35: 434-442 (1992).

• Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080 (1992).

• Badenhoop K, Schwarz G, Schleusener H, Weetman AP, Recks S, Peters H, Bottazzo GF, Usadel KH. Tumor necrosis factor beta gene polymorphisms in Graves' disease. J. Clin. Endocrinol. Metab. 74: 287-291 (1992).

• Baines M, Ebringer A. HLA and disease. Mol. Aspects Med. 13: 263-378 (1992). *

• Balda MS, Fallon MB, Van Itallie CM, Anderson JM. Structure, regulation, and pathophysiology of tight junctions in the gastrointestinal tract. Yale J. Biol. Med. 65: 725-735 (1992). *

• Barthauer L, Tarter R, Hirsch W, Van Thiel D. Brain morphologic characteristics of cirrhotic alcoholics and cirrhotic nonalcoholics: an MRI study. Alcohol Clin. Exp. Res. 16: 982-985 (1992).

• Bartsch H, Ohshima H, Pignatelli B, Calmels S. Endogenously formed N-nitroso compounds and nitrosating agents in human cancer etiology. Pharmacogenetics 2: 272-277 (1992).

• Bassendine MF, Yeaman SJ. Serological markers of primary biliary cirrhosis: diagnosis, prognosis and subsets. Hepatology 15: 545-548 (1992).

• Beagley KW, Elson CO. Cells and cytokines in mucosal immunity and inflammation. Gastroenterol. Clin. North Am. 21: 347-366 (1992).

• Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc. Biol. Sci. 247: 83-87 (1992).

• Behrens R, Ruder H. Chronic inflammatory intestinal disease and nephritis. Klin. Padiatr. 204: 61-64 (1992).

• Beier K, Volkl A, Fahimi HD. Suppression of peroxisomal lipid beta-oxidation enzymes of TNF-alpha. FEBS Lett. 310: 273-276 (1992).

• Benbassat C, Schlesinger M, Shoenfeld Y. The complement system and primary biliary cirrhosis. J. Clin. Lab. Immunol. 38: 51-61 (1992).

• Benjamin R, Parham P. HLA-B27 and disease: a consequence of inadvertent antigen presentation? Rheum. Dis. Clin. North Am. 18: 11-21 (1992).

• Beppu T, Maruyama T, Ohashi K, Ohura S, Nakanishi R, Fukasawa M, Futagawa S. Results of non-decompression surgery for esophago-gastric varices - postoperative disappearance, recurrence, rebleeding rate of varices, and cumulative survival rate. Nippon Geka Gakkai Zasshi 93: 1159-1163 (1992).

• Berdal A. Vitamin D: biosynthesis, metabolism and mechanism of action at the cellular level. J. Biol. Buccale. 20: 71-83 (1992).

• Berg CL, Gollan JL. Primary biliary cirrhosis: new therapeutic directions. Scand. J. Gastroenterol. Suppl. 192: 43-49 (1992).

• Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig. Dis. 10: 85-101 (1992).

• Berg PA, Klein R. Immunological diagnosis in non-viral liver diseases. Schweiz. Rundsch. Med. Prax. 81: 793-794 (1992).

• Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis. A clue to its etiopathogenesis? J. Hepatol. 15: 6-9 (1992).

• Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102: 544-549 (1992).

• Berr F, Holl J, Jungst D, Fischer S, Richter WO, Seifferth B, Paumgartner G. Dietary n-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease. Hepatology 16: 960-967 (1992). *

• Berr F, Pratschke E, Fischer S, Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J. Clin. Invest. 90: 859-868 (1992). *

• Berr F, Schreiber E, Frick U. Interrelationships of bile acid and phospholipid fatty acid species with cholesterol saturation of duodenal bile in health and gallstone disease. Hepatology 16: 71-81 (1992).

• Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16: 707-714 (1992).

• Beuers U, Spengler U, Sackmann M, Paumgartner G, Sauerbruch T. Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis. J. Hepatol. 15: 140-143 (1992).

• Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15: 603-608 (1992).

• Beukers R, de Rave S, van den Berg JW, Schalm SW. Oral pharmacokinetics of cyclosporin in patients with primary biliary cirrhosis and patients with skin diseases. Aliment. Pharmacol. Ther. 6: 459-468 (1992).

• Beukers R, van Zanten RA, Schalm SW. Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis. J. Hepatol. 14: 22-29 (1992).

• Bissuel F, Bizollon T, Dijoud F, Bouletreau P, Cordier JF, Chazot C, Gouillat C, Trepo C. Pulmonary hemorrhage and glomerulonephritis in primary biliary cirrhosis. Hepatology 16: 1357-1361 (1992).

• Blackburn GL. Nutrition and inflammatory events: highly unsaturated fatty acids (omega-3 vs omega-6) in surgical injury. Proc. Soc. Exp. Biol. Med. 200: 183-188 (1992).

• Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, Gremy F, Michel H. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 15: 222-228 (1992).

• Blann AD, Babbs C, Neuberger JM. Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms. Clin. Exp. Immunol. 90: 88-92 (1992). *

• Blasco A, Dominguez P, Colina F, Castellano G. Wilson's disease. A histological review of 7 patients and the value of histological copper positivity in relation to other hepatopathies. Med. Clin. (Barc.) 98: 207-211 (1992).

• Blomhoff HK, Smeland EB, Erikstein B, Rasmussen AM, Skrede B, Skjønsberg C, Blomhoff R. Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells. J. Biol. Chem. 267: 23988-23992 (1992). *

• Blumberg B, Mangelsdorf DJ, Dyck JA, Bittner DA, Evans RM, De Robertis EM. Multiple retinoid-responsive receptors in a single cell: families of retinoid "X" receptors and retinoic acid receptors in the Xenopus egg. Proc. Natl. Acad. Sci. U.S.A. 89: 2321-2325 (1992). *

• Bohren KM, Grimshaw CE, Gabbay KH. Catalytic effectiveness of human aldose reductase. Critical role of C-terminal domain. J. Biol. Chem. 267: 20965-20970 (1992). *

• Boki KA, Panayi GS, Vaughan RW, Drosos AA, Moutsopoulos HM, Lanchbury JS. HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients. Arthritis Rheum. 35: 749-755 (1992).

• Bottomley WW, Cunliffe WJ. Acute Achilles tendonitis following oral isotretinoin therapy for acne vulgaris. Clin. Exp. Dermatol. 17: 250-251 (1992).

• Bozzette SA, Gordon RL, Yen A, Rinaldi M, Ito MK, Fierer J. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin. Infect. Dis. 15: 701-703 (1992).

• Braun WE. HLA molecules in autoimmune diseases. Clin. Biochem. 25: 187-191 (1992). *

• Brautbar N, Vojdani A, Campbell AW. Silicone implants and systemic immunological disease: review of the literature and preliminary results. Toxicol. Ind. Health 8: 231-237 (1992).

• Bray GP, Williams R. Immunointervention in primary biliary cirrhosis: an overview. J. Autoimmun. 5 Suppl. A: 293-300 (1992).

• Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 42: 1798-1804 (1992).

• Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, Tummler B. Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur. J. Biochem. 206: 137-149 (1992). *

• Bresson JL, Schmitz J. Malnutrition in Crohn's disease: substrate deficiency or misuse? Horm. Res. 38 Suppl. 1: 76-78 (1992).

• Briand JP, Andre C, Tuaillon N, Herve L, Neimark J, Muller S. Multiple autoepitope presentation for specific detection of antibodies in primary biliary cirrhosis. Hepatology 16: 1395-1403 (1992).

• Brookes SM, Pandolfino YA, Mitchell TJ, Venables PJ, Shattles WG, Clark DA, Entwistle A, Maini RN. The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br. J. Rheumatol. 31: 735-742 (1992).

• Broome U, Eriksson LS, Sundin U, Sundqvist KG. Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis patients. Scand. J. Gastroenterol. 27: 124-128 (1992).

• Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis - a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 102: 1877-1880 (1992).

• Brown WJ, Hudson MJ, Patrick S, Matthews SC, Hill MJ, Gent AE, Grace RH, Hellier MD, Swarbrick ET. Search for enteric microbial pathogens in patients with ulcerative colitis. Digestion 53: 121-128 (1992).

• Bruguera M, Llach J, Rodes J. Nonsyndromic paucity of intrahepatic bile ducts in infancy and idiopathic ductopenia in adulthood: the same syndrome? Hepatology 15: 830-834 (1992).

• Brunner G. The therapy of chronic destructive nonsuppurative cholangitis. Dtsch. Med. Wochenschr. 117: 1984 (1992).

• Brunt EM, Swanson PE. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. Am. J. Clin. Pathol. 97: S53-S61 (1992).

• Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC, Rubin CE. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103: 1602-1610 (1992).

• Burra P, Elias E. Vanishing bile duct syndrome. Br. J. Surg. 79: 604-605 (1992).

• Burroughs AK, Butler P, Sternberg MJ, Baum H. Molecular mimicry in liver disease. Nature 358: 377-378 (1992). *

• Burt RW, Bishop DT, Cannon-Albright L, Samowitz WS, Lee RL, DiSario JA, Skolnick MH. Population genetics of colonic cancer. Cancer 70: 1719-1722 (1992).

• Caldwell SH, Leung PS, Spivey JR, Prindiville T, de Medina M, Saicheur T, Rowley M, Reddy KR, Coppel R, Jeffers LJ, et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 16: 899-905 (1992).

• Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 102: 1371-1377 (1992).

• Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 16: 719-723 (1992).

• Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 103: 617-621 (1992).

• Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 33: 668-674 (1992). *

• Cameron JL. Primary sclerosing cholangitis: palliative surgery or transplantation? HPB Surg. 5: 275-277 (1992). *

• Campbell PW 3rd, Phillips JA 3rd. The cystic fibrosis gene and relationships to clinical status. Semin. Respir. Infect. 7: 150-157 (1992).

• Campieri M, Bertinelli E, Gionchetti P, Belluzzi A, Tampieri M, Brignola C, Miglioli M, Barbara L. Requirements for the use of intestinal action antibiotics in the treatment of ulcerative colitis. Ital. J. Gastroenterol. 24: S2-S3 (1992).

• Campieri M, Corbelli C, Gionchetti P, Brignola C, Belluzzi A, Di Febo G, Zagni P, Brunetti G, Miglioli M, Barbara L. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig. Dis. Sci. 37: 1890-1897 (1992).

• Canfield LM, Forage JW, Valenzuela JG. Carotenoids as cellular antioxidants. Proc. Soc. Exp. Biol. Med. 200: 260-265 (1992).

• Capobianchi MR, Fais S, Di Paolo MC, Agostini D, Paoluzi P, Pallone F, Dianzani F. Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology. Clin. Exp. Immunol. 90: 85-87 (1992). *

• Carey WD, Patel G. Viral hepatitis in the 1990s, Part III: Hepatitis C, hepatitis E, and other viruses. Cleve. Clin. J. Med. 59: 595-601 (1992).

• Carpenter HA, Tremaine WJ, Batts KP, Czaja AJ. Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig. Dis. Sci. 37: 1903-1909 (1992).

• Castaldo P, Grazi GL, Wood RP, Markin RS, Stratta RJ, Langnas AN, Clark JH, Shaw BW Jr. An unusual case of choledochal cyst causing hepatic failure requiring orthotopic liver transplantation. J. Pediatr. Surg. 27: 1557-1559 (1992).

• Castellano G, Colina F, Moreno D, Pinedo F, Canga F, Solis Herruzo JA. Nodular regenerative hepatic hyperplasia associated with primary biliary cirrhosis. Rev. Clin. Esp. 191: 433-434 (1992).

• Cecchi L, Gianni R, Santoro E, Leopardi A, Taccetti G, Baruffi MC, Cappelletti C. Thrombosis of the superior sagittal sinus and ulcerative colitis. A case report. Ann. Ital. Med. Int. 7: 176-178 (1992).

• Chamuleau RA, Diekman MJ, Bos PJ, Smitt JH, Bosma A, Schellekens PT. Reappearance of vanished bile ducts. Hepatogastroenterology 39: 523-524 (1992).

• Chang SW, Ohara N. Pulmonary circulatory dysfunction in rats with biliary cirrhosis. An animal model of the hepatopulmonary syndrome. Am. Rev. Respir. Dis. 145: 798-805 (1992).

• Chaouni I, Lefranc MP, d'Angeac AD, Zanin C, Pellet F, Clot J, Combe B, Sany J, Reme T. T cell receptor gamma variable gene locus polymorphism in patients with rheumatoid arthritis. Arthritis Rheum. 35: 756-760 (1992).

• Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol. Biochem. Behav. 43: 423-431 (1992).

• Charron DJ. New aspects of HLA: perspectives for rheumatoid arthritis. Clin. Exp. Rheumatol. 10: 293-296 (1992).

• Chatila T, Geha RS. Superantigens. Curr. Opin. Immunol. 4: 74-78 (1992).

• Chen J, Compton C, Cheng E, Fromowitz F, Viola MV. c-Ki-ras mutations in dysplastic fields and cancers in ulcerative colitis. Gastroenterology 102: 1983-1987 (1992).

• Chesta J, Brahm J, Varas V, Macaya P, Latorre R, Smok G, Morales A. Peptic ulcer and endoscopic signs of portal hypertension in patients with primary biliary cirrhosis. Rev. Med. Chil. 120: 768-771 (1992).

• Chien RN, Sheen IS, Chen TJ, Liaw YF. A clinicopathological study in primary biliary cirrhosis. J. Formos. Med. Assoc. 91 Suppl. 2: S117-S121 (1992).

• Choi PM, Nugent FW, Rossi RL. Relationship between colorectal neoplasia and primary sclerosing cholangitis in ulcerative colitis. Gastroenterology 103: 1707-1709 (1992).

• Chou MJ, Lai MY, Lee SL, Tsay GJ. Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis. J. Formos. Med. Assoc. 91: 1075-1080 (1992).

• Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical … J. Clin. Invest. 90: 785-790 (1992). *

• Clarke LL, Grubb BR, Gabriel SE, Smithies O, Koller BH, Boucher RC. Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science 257: 1125-1128 (1992). *

• Colina F, Pinedo F, Solis JA, Moreno D, Nevado M. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 102: 1319-1324 (1992).

• Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 256: 774-779 (1992). *

• Collins FS, Wilson JM. Cystic fibrosis. A welcome animal model. Nature 358: 708-709 (1992). *

• Colombel JF, Reumaux D, Duthilleul P, Noel LH, Gower-Rousseau C, Paris JC, Cortot A. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol. Clin. Biol. 16: 656-660 (1992).

• Colombo C, Apostolo MG, Assaisso M, Roman B, Bottani P. Liver disease in cystic fibrosis. Neth. J. Med. 41: 119-122 (1992).

• Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 15: 677-684 (1992).

• Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, Zimmer-Nechemias L, Setchell KD. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 16: 924-930 (1992).

• Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Natl. Acad. Sci. U.S.A. 89: 3932-3936 (1992). *

• Congia M, Frau F, Lampis R, Frau R, Mele R, Cucca F, Muntoni F, Porcu S, Boi F, Contu L, et al. A high frequency of the A30, B18, DR3, DRw52, DQw2 extended haplotype in Sardinian celiac disease patients: further evidence that disease susceptibility is conferred by DQ A1*0501, B1*0201. Tissue Antigens 39: 78-83 (1992).

• Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 339: 1279-1281 (1992).

• Cox NL, Prowse MV, Maddison MC, Maddison PJ. Treatment of early rheumatoid arthritis with rifampicin. Ann. Rheum. Dis. 51: 32-34 (1992). *

• Cravo ML, Mason JB, Dayal Y, Hutchinson M, Smith D, Selhub J, Rosenberg IH. Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats. Cancer Res. 52: 5002-5006 (1992). *

• Crippin JS, Gross JB Jr, Lindor KD. Increased intracranial pressure and hepatic encephalopathy in chronic liver disease. Am. J. Gastroenterol. 87: 879-882 (1992).

• Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, Dickson ER. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 15: 858-862 (1992).

• Crivellari D, Cannizzaro R, Galligioni E, Valentini M, Monfardini S, Castiglione M. Adjuvant therapy for primary breast cancer in a female patient affected by autoimmune liver disease: does it cure breast cancer and primary biliary cirrhosis? Tumori. 78: 395-396 (1992).

• Czaja AJ. Chronic hepatitis C virus infection - a disease in waiting? N. Engl. J. Med. 327: 1949-1950 (1992).

• Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103: 1290-1295 (1992).

• Czaja AJ, Taswell HF, Rakela J, Rabe D. Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. Gastroenterology 102: 1675-1679 (1992).

• Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. J. Hepatol. 14: 88-93 (1992).

• Czernichow B, Dufour P, Doffoel M. Late onset serum IgA and IgM deficiency revealed by acute diarrhea caused by Aeromonas sobria infection. Gastroenterol. Clin. Biol. 16: 476-477 (1992).

• Das KM, Squillante L, Chitayet D, Kalousek DK. Simultaneous appearance of a unique common epitope in fetal colon, skin, and biliary epithelial cells. A possible link for extracolonic manifestations in ulcerative colitis. J. Clin. Gastroenterol. 15: 311-316 (1992).

• Das KM, Squillante L, Robertson F. Expression of the 40 kD protein in DLD-1 colon cancer cells and the effect of cytokines. Clin. Exp. Immunol. 88: 138-142 (1992). *

• Das KM, Vecchi M, Squillante L, Dasgupta A, Henke M, Clapp N. Mr 40,000 human colonic epithelial protein expression in colonic mucosa and presence of circulating anti-Mr 40,000 antibodies in cotton top tamarins with spontaneous colitis. Gut 33: 48-54 (1992). *

• Davies GR, Simmonds NJ, Stevens TR, Grandison A, Blake DR, Rampton DS. Mucosal reactive oxygen metabolite production in duodenal ulcer disease. Gut 33: 1467-1472 (1992). *

• Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br. J. Cancer 66: 777-780 (1992).

• Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA, Dickson ER, Krawitt E, Coppel R, Gershwin ME. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 16: 1128-1136 (1992).

• De Arce M, O'Brien S, Hegarty J, O'Mahoney SM, Cashman SM, Martinez A, Delgado M, FitzGerald MX. Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease. Clin. Genet. 42: 271-272 (1992).

• de Laat PC, Weemaes CM, Bakkeren JA. Immunoglobulin levels during follow-up of children with selective IgA deficiency. Scand. J. Immunol. 35: 719-725 (1992).

• de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother. 36: 2192-2196 (1992). *

• de Montalembert M, Lenoir G, Saint-Raymond A, Rey J, Lefrere JJ. Increased PIVKA-II concentrations in patients with cystic fibrosis. J. Clin. Pathol. 45: 180-181 (1992). *

• De Pauw M, Voet D, Kunnen M, Barbier F, Afschrift M. Arcuate ligament syndrome mimicking celiac occlusion. Am. J. Gastroenterol. 87: 1482-1484 (1992).

• de Vries DD, Dekker-Saeys AJ, Gyodi E, Bohm U, Ivanyi P. Absence of autoantibodies to peptides shared by HLA-B27.5 and Klebsiella pneumoniae nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome. Ann. Rheum. Dis. 51: 783-789 (1992). *

• Degli-Esposti MA, Abraham LJ, McCann V, Spies T, Christiansen FT, Dawkins RL. Ancestral haplotypes reveal the role of the central MHC in the immunogenetics of IDDM. Immunogenetics 36: 345-356 (1992).

• Degli-Esposti MA, Andreas A, Christiansen FT, Schalke B, Albert E, Dawkins RL. An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 35: 355-364 (1992).

• Degli-Esposti MA, Leelayuwat C, Dawkins RL. Ancestral haplotypes carry haplotypic and haplospecific polymorphisms of BAT1: possible relevance to autoimmune disease. Eur. J. Immunogenet. 19: 121-127 (1992).

• Deighton CM, Fay A, Walker DJ. Rheumatoid arthritis in thyroid disease positive and negative same-sexed sibships. Br. J. Rheumatol. 31: 13-17 (1992).

• Delboy H. Mode of action of sulfasalazine in chronic inflammatory enterocolonic diseases. Therapie 47: 157-159 (1992).

• Delle Monache M, Salvio A, Fiocca F, Basoli A, Ricci GL. Primary sclerosing cholangitis: an analysis of 37 retrospective cases. Ital. J. Gastroenterol. 24: 485-488 (1992).

• Delmonico FL, Jenkins RL, Freeman R, Vacanti J, Bradley J, Dienstag JL, Trey C, Lewis WD, Lillehei CW, Auchincloss H Jr. The high-risk liver allograft recipient. Should allocation policy consider outcome? Arch. Surg. 127: 579-584 (1992).

• DeLuca HF. New concepts of vitamin D functions. Ann. N. Y. Acad. Sci. 669: 59-68 (1992).

• Denning GM, Ostedgaard LS, Cheng SH, Smith AE, Welsh MJ. Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. J. Clin. Invest. 89: 339-349 (1992). *

• Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J. Cell Biol. 118: 551-559 (1992).

• Deschamps I, Khalil I. The role of the HLA system in the genetics of type I diabetes mellitus. Diabete. Metab. 18: 253-263 (1992).

• Desmet VJ. Vanishing bile duct disorders. Prog. Liver Dis. 10: 89-121 (1992).

• Devlin JW, Bellamy N, Bayliff CD. Observations and effects of educational consults on allopurinol prescribing. Can. J. Hosp. Pharm. 45: 21-27 (1992).

• Di Febo G, Calabrese C, Matassoni F. New trends in non-absorbable antibiotics in gastrointestinal disease. Ital. J. Gastroenterol. 24: S10-S13 (1992).

• Dias VC, Wallace JL, Parsons HG. Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2). Gut 33: 622-627 (1992). *

• Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, Malinchoc M, Chapman RW, Kaplan MM, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103: 1893-1901 (1992).

• Dilawari JB, Chawla YK. Pseudosclerosing cholangitis in extrahepatic portal venous obstruction. Gut 33: 272-276 (1992). *

• Dinarello CA. Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases. Semin. Immunol. 4: 133-145 (1992).

• Dong YS, Huang ZH, Wu LF. Treatment of infantile hepatitis syndrome with injection of yin zhi huang. Zhongguo Zhong Xi Yi Jie He Za Zhi 12: 26-27, 5-6 (1992).

• Drake CG, Kotzin BL. Superantigens: biology, immunology, and potential role in disease. J. Clin. Immunol. 12: 149-162 (1992).

• Duell EA, Astrom A, Griffiths CE, Chambon P, Voorhees JJ. Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. J. Clin. Invest. 90: 1269-1274 (1992). *

• Duthie A, Doherty DG, Williams C, Scott-Jupp R, Warner JO, Tanner MS, Williamson R, Mowat AP. Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology 15: 660-664 (1992).

• Eager NS, Brickell PM, Snell C, Wood JN. Structural and functional evidence for activation of a chick retinoid X receptor by eicosanoids. Proc. Biol. Sci. 250: 63-69 (1992). *

• Eberle M, Baxter-Lowe LA. Molecular analysis of HLA-DRB1*08/12 alleles: identification of two additional alleles. Hum. Immunol. 34: 24-30 (1992).

• Ebringer A. Ankylosing spondylitis is caused by Klebsiella. Evidence from immunogenetic, microbiologic, and serologic studies. Rheum. Dis. Clin. North Am. 18: 105-121 (1992).

• Elkhalifa MY, Kiechle FL, Gordon SC, Chen J, Poulik MD. A flow cytometric method to detect anti-pyruvate dehydrogenase antibody in primary biliary cirrhosis. Am. J. Clin. Pathol. 97: 202-208 (1992).

• Ellis HJ, Doyle AP, Sturgess RP, Ciclitira PJ. Coeliac disease: characterisation of monoclonal antibodies raised against a synthetic peptide corresponding to amino acid residues 206-217 of A-gliadin. Gut 33: 1504-1507 (1992). *

• Elsaghier A, Prantera C, Bothamley G, Wilkins E, Jindal S, Ivanyi J. Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Clin. Exp. Immunol. 89: 305-309 (1992). *

• Elsaghier A, Prantera C, Moreno C, Ivanyi J. Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease. Clin. Exp. Immunol. 90: 503-508 (1992). *

• Enriquez G, Lucaya J, Allende E, Garcia-Pena P. Intrahepatic biliary stones in children. Pediatr. Radiol. 22: 283-286 (1992).

• Enzenauer RJ, West SG. Sarcoidosis in autoimmune disease. Semin. Arthritis Rheum. 22: 1-17 (1992).

• Epstein CM, Riether AM, Henderson RM, Cotsonis GA. EEG in liver transplantation: visual and computerized analysis. Electroencephalogr. Clin. Neurophysiol. 83: 367-371 (1992).

• Erlinger S. Cystic fibrosis: bile secretion. Br. Med. Bull. 48: 860-876 (1992).

• Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol. Clin. North Am. 21: 751-776 (1992).

• Everson GT, Daggy BP, McKinley C, Story JA. Effects of Psyllium hydrophilic mucilloid on LDL-cholesterol and bile acid synthesis in hypercholesterolemic men. J. Lipid Res. 33: 1183-1192 (1992). *

• Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am. J. Med. 93: 299-302 (1992).

• Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, Eddleston AL, Williams R. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 16: 390-395 (1992).

• Ferec C, Audrezet MP, Mercier B, Guillermit H, Moullier P, Quere I, Verlingue C. Detection of over 98% cystic fibrosis mutations in a Celtic population. Nat. Genet. 1: 188-191 (1992). *

• Feuer G, Di Fonzo CJ. Intrahepatic cholestasis: a review of biochemical-pathological mechanisms. Drug Metabol. Drug Interact. 10: 1-161 (1992).

• Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int. 42: 951-956 (1992).

• Floreani A, Chiaramonte M, Venturini R, Plebani M, Martin A, Giacomini A, Naccarato R. Antigliadin antibody classes in chronic liver disease. Ital. J. Gastroenterol. 24: 457-460 (1992).

• Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 102: 1385-1388 (1992).

• Fox MF, Lahbib F, Pratt W, Attwood J, Gum J, Kim Y, Swallow DM. Regional localization of the intestinal mucin gene MUC3 to chromosome 7q22. Ann. Hum. Genet. 56: 281-287 (1992).

• Freeman M, Weetman AP. T and B cell reactivity to adrenal antigens in autoimmune Addison's disease. Clin. Exp. Immunol. 88: 275-279 (1992). *

• Frezza M, Terpin MM, Peri A. S-Adenosyl-L-methionine (SAMe) and its use in hepatology. Minerva Gastroenterol. Dietol. 38: 145-151 (1992).

• Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629 (1992).

• Friman S, Persson H, Karlberg I, Svanvik J. The bile acid independent flow is reduced in the transplanted liver. Transpl. Int. 5 Suppl. 1: S163-S167 (1992).

• Friman S, Persson H, Schersten T, Svanvik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transpl. Int. 5 Suppl. 1: S187-S189 (1992).

• Fromm H. New treatment for primary sclerosing cholangitis: promising results with ursodiol. Gastroenterology 103: 343-344 (1992).

• Fukumoto Y, Ando M, Yasunaga M, Okuda M, Okita K. Effects of secretin on bile production in two kinds of cholestatic models by choledocho-caval fistula and bile duct ligation in rats. Gastroenterol. Jpn. 27: 396-404 (1992).

• Fukutomi T, Sakamoto S, Isobe H, Sakai H, Masumoto A, Nawata H. Clinical significance of the serum levels of the 7S domain of type IV collagen in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 7: 596-601 (1992).

• Funkhouser SW, Concannon P, Charmley P, Vredevoe DL, Hood L. Differences in T cell receptor restriction fragment length polymorphisms in patients with rheumatoid arthritis. Arthritis Rheum. 35: 465-471 (1992).

• Fusconi M, Baum H, Caselli A, Cassani F, Ballardini G, Lenzi M, Volta U, Zauli D, Bianchi FB. Demonstration of peptide-specific and cross-reactive epitopes in proteins reacting with antimitochondrial antibodies of primary biliary cirrhosis. J. Hepatol. 15: 162-169 (1992).

• Geier DL, Miner PB Jr. New therapeutic agents in the treatment of inflammatory bowel disease. Am. J. Med. 93: 199-208 (1992).

• Gerard-Boncompain M, Claudel JP, Gaussorgues P, Salord F, Sirodot M, Chevallier M, Robert D. Hepatic cytolytic and cholestatic changes related to a change of lipid emulsions in four long-term parenteral nutrition patients with short bowel. JPEN J. Parenter. Enteral Nutr. 16: 78-83 (1992).

• Gershwin ME, Rowley M, Davis PA, Leung P, Coppel R, Mackay IR. Molecular biology of the 2-oxo-acid dehydrogenase complexes and anti-mitochondrial antibodies. Prog. Liver Dis. 10: 47-61 (1992).

• Ghazal P, DeMattei C, Giulietti E, Kliewer SA, Umesono K, Evans RM. Retinoic acid receptors initiate induction of the cytomegalovirus enhancer in embryonal cells. Proc. Natl. Acad. Sci. U.S.A. 89: 7630-7634 (1992). *

• Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33: 646-650 (1992). *

• Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment. Pharmacol. Ther. 6: 51-59 (1992).

• Giardiello FM, Lazenby AJ, Yardley JH, Bias WB, Johnson J, Alianiello RG, Bedine MS, Bayless TM. Increased HLA A1 and diminished HLA A3 in lymphocytic colitis compared to controls and patients with collagenous colitis. Dig. Dis. Sci. 37: 496-499 (1992).

• Gibson PR, Pavli P. Pathogenic factors in inflammatory bowel disease. I. Ulcerative colitis. Dig. Dis. 10: 17-28 (1992).

• Gil Gonzalez I, Gonzalez Hernandez JM, Velicia Llames R. Primary sclerosing cholangitis and inflammatory intestinal disease. An. Med. Interna. 9: 568 (1992).

• Ginn P, Workman RD. Primary biliary cirrhosis and adult celiac disease. West. J. Med. 156: 547-549 (1992).

• Gjersten HA, Lundin KE, Kwok WW, Nepom GT, Thorsby E. Allorecognition of HLA-DQw8 molecules: influence of single amino acid substitutions. Tissue Antigens 39: 95-98 (1992).

• Gobbi G, Ambrosetto P, Zaniboni MG, Lambertini A, Ambrosioni G, Tassinari CA. Celiac disease, posterior cerebral calcifications and epilepsy. Brain Dev. 14: 23-29 (1992).

• Goenka MK, Mehta SK, Malik AK, Kumar YR, Kochhar R. Fatal pulmonary arterial hypertension complicating noncirrhotic portal fibrosis. Am. J. Gastroenterol. 87: 1203-1205 (1992).

• Goldberg HI. Imaging of the biliary tract. Curr. Opin. Radiol. 4: 62-69 (1992).

• Goodnick PJ, Sandoval R, Brickman A, Klimas NG. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol. Psychiatry 32: 834-838 (1992).

• Gran JT, Husby G. Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn's disease. Dig. Dis. 10: 274-294 (1992).

• Greenwald BD, Harpaz N, Yin J, Huang Y, Tong Y, Brown VL, McDaniel T, Newkirk C, Resau JH, Meltzer SJ. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res. 52: 741-745 (1992). *

• Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J. Am. Acad. Dermatol. 26: 371-383 (1992).

• Griffiths MR, Shepherd M, Ferrier R, Schuppan D, James OF, Burt AD. Light microscopic and ultrastructural distribution of type VI collagen in human liver: alterations in chronic biliary disease. Histopathology 21: 335-344 (1992).

• Gross EG, Helfgott MA. Retinoids and the eye. Dermatol. Clin. 10: 521-531 (1992).

• Gross JB Jr. Prognosis in chronic liver diseases: Cox models, quantitative liver function tests, or both? Gastroenterology 103: 1360-1361 (1992).

• Gross S, Blaiss MS, Herrod HG. Role of immunoglobulin subclasses and specific antibody determinations in the evaluation of recurrent infection in children. J. Pediatr. 121: 516-522 (1992).

• Gu JJ, Hofmann AF, Ton-Nu HT, Schteingart CD, Mysels KJ. Solubility of calcium salts of unconjugated and conjugated natural bile acids. J. Lipid Res. 33: 635-646 (1992). *

• Guanabens N, Pares A, del Rio L, Roca M, Gomez R, Munoz J, Rodes J. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J. Hepatol. 15: 345-349 (1992).

• Guarner F, Vilaseca J, Malagelada JR. Dietary manipulation in experimental inflammatory bowel disease. Agents Actions Spec. No.: C10-C14 (1992).

• Guldner HH, Szostecki C, Grotzinger T, Will H. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J. Immunol. 149: 4067-4073 (1992).

• Guldutuna S, Leuschner U, Imhof M, Zimmer G. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid. Z. Gastroenterol. 30 Suppl. 1: 49-54 (1992).

• Gut J, Christen U, Huwyler J, Burgin M, Kenna JG. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur. J. Biochem. 210: 569-576 (1992).

• Hadchouel M. Paucity of interlobular bile ducts. Semin. Diagn. Pathol. 9: 24-30 (1992).

• Hakala M, Ilonen J, Reijonen H, Knip M, Koivisto O, Isomaki H. No association between rheumatoid arthritis and insulin dependent diabetes mellitus: an epidemiologic and immunogenetic study. J. Rheumatol. 19: 856-858 (1992).

• Halbwachs-Mecarelli L, Nusbaum P, Noel LH, Reumaux D, Erlinger S, Grunfeld JP, Lesavre P. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin. Exp. Immunol. 90: 79-84 (1992). *

• Hallenbeck PL, Marks MS, Lippoldt RE, Ozato K, Nikodem VM. Heterodimerization of thyroid hormone (TH) receptor with H-2RIIBP (RXR beta) enhances DNA binding and TH-dependent transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 89: 5572-5576 (1992). *

• Harada N, Dohmen K, Itoh H, Ohshima T, Yamamoto H, Nagano M, Iwata Y, Hachisuka K, Ishibashi H. Sibling cases of primary biliary cirrhosis associated with polymyositis, vasculitis and Hashimoto's thyroiditis. Intern. Med. 31: 289-293 (1992). *

• Harrington AC, Fitzpatrick JE. Cutaneous sarcoidal granulomas in a patient with primary biliary cirrhosis. Cutis 49: 271-274 (1992).

• Harris CE, Griffiths RD, Freestone N, Billington D, Atherton ST, Macmillan RR. Intestinal permeability in the critically ill. Intensive Care Med. 18: 38-41 (1992).

• Hartleb M, Jasinski B, Wolanska-Karut J, Rudzka J. Recurrent benign intrahepatic cholestasis syndrome. Pol. Arch. Med. Wewn. 87: 144-148 (1992).

• Haruta J, Kusugami K, Kuroiwa A, Ina K, Shinoda M, Morise K, Iokawa H, Morita M, Ishihara A, Sarai S. Phenotypic and functional analysis of lamina propria mononuclear cells from colonoscopic biopsy specimens in patients with ulcerative colitis. Am. J. Gastroenterol. 87: 448-454 (1992).

• Hassan AS, Bunick D, Lund LA, Bottje WG. Glutathione and bile acid synthesis. Effect of GSH content of HepG2 cells on the activity and mRNA levels of cholesterol 7 alpha-hydroxylase. Biochem. Pharmacol. 44: 1475-1477 (1992).

• Hawes DR, Pelsang RE, Janda RC, Lu CC. Imaging of the biliary sump syndrome. AJR Am. J. Roentgenol. 158: 315-319 (1992). *

• Hawkey CJ, Mahida YR, Hawthorne AB. Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators. Agents Actions Spec. No: C22-C26 (1992).

• Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, Malkinson C, Shaheen MZ, Willars JE. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33: 922-928 (1992). *

• Heath JK, Suva LJ, Yoon K, Kiledjian M, Martin TJ, Rodan GA. Retinoic acid stimulates transcriptional activity from the alkaline phosphatase promoter in the immortalized rat calvarial cell line, RCT-1. Mol. Endocrinol. 6: 636-646 (1992). *

• Hebbard GS, Smith KG, Gibson PR, Bhathal PS. Augmentin-induced jaundice with a fatal outcome. Med. J. Aust. 156: 285-286 (1992).

• Heimburger DC. Localized deficiencies of folic acid in aerodigestive tissues. Ann. N. Y. Acad. Sci. 669: 87-95 (1992). *

• Heinrich I, Nashitz J, Yeshurun D. Combined cholestatic jaundice due to cholelithiasis and primary biliary cirrhosis. Harefuah. 123: 392-394, 435 (1992).

• Heuman DM, Vlahcevic ZR, Pandak WM, Hylemon PB, Kim YS, Lillienau J, Hofmann AF. Effect of cholylsarcosine on hepatic cholesterol and bile acid synthesis and bile secretion in rats. Gastroenterology 103: 1641-1648 (1992).

• Hewison M. Vitamin D and the immune system. J. Endocrinol. 132: 173-175 (1992).

• Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C. 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68: 397-406 (1992). *

• Higuchi T, Hishida N, Isomura T, Takeshima H, Hayashi H. The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids. Gastroenterol. Jpn. 27: 222-229 (1992).

• Hillstrom J, Duane WC, Eckfeldt JH, Furne J, Levitt MD. Lack of benefit of ursodeoxycholic acid in drug-induced cholestasis in the rat. Proc. Soc. Exp. Biol. Med. 200: 122-126 (1992).

• Hoang P, Crotty B, Dalton HR, Jewell DP. Epithelial cells bearing class II molecules stimulate allogeneic human colonic intraepithelial lymphocytes. Gut 33: 1089-1093 (1992). *

• Hodgson HJ. Immunological aspects of inflammatory bowel diseases of the human gut. Agents Actions 1992 Spec. No: C27-C31 (1992).

• Hodin RA, Chamberlain SM, Upton MP. Thyroid hormone differentially regulates rat intestinal brush border enzyme gene expression. Gastroenterology 103: 1529-1536 (1992).

• Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116: 488-498 (1992).

• Hofmann AF, Mysels KJ. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J. Lipid Res. 33: 617-626 (1992). *

• Hofmann AF, Sjovall J, Kurz G, Radominska A, Schteingart CD, Tint GS, Vlahcevic ZR, Setchell KD. A proposed nomenclature for bile acids. J. Lipid Res. 33: 599-604 (1992). *

• Hollo G, Szalay F. Dry eye syndrome in patients with biliary cirrhosis. Orv. Hetil. 133: 2217-2220 (1992).

• Holm K, Maki M, Savilahti E, Lipsanen V, Laippala P, Koskimies S. Intraepithelial gamma delta T-cell-receptor lymphocytes and genetic susceptibility to coeliac disease. Lancet 339: 1500-1503 (1992).

• Hoopes CW, Taketo M, Ozato K, Liu Q, Howard TA, Linney E, Seldin MF. Mapping of the mouse Rxr loci encoding nuclear retinoid X receptors RXR alpha, RXR beta, and RXR gamma. Genomics 14: 611-617 (1992).

• Horita M, Takahashi N, Seike M, Nasu S, Takaki R. A case of primary biliary cirrhosis associated with Hashimoto's thyroiditis, scleroderma and Sjogren's syndrome. Intern. Med. 31: 418-421 (1992). *

• Hoso M, Nakanuma Y. Argyrophilic nucleolar organizer regions in neoplastic and non-neoplastic hepatocytes bearing Mallory bodies. Liver 12: 112-115 (1992).

• Huan B, Siddiqui A. Retinoid X receptor RXR alpha binds to and trans-activates the hepatitis B virus enhancer. Proc. Natl. Acad. Sci. U.S.A. 89: 9059-9063 (1992). *

• Huang F, Cai XH, Shi GY. Role of enteric Klebsiella pneumonia infection and HLA-B27 in ankylosing spondylitis. Zhonghua Nei Ke Za Zhi 31: 398-400, 443 (1992).

• Hubbard AM, Meyer JS, Mahboubi S. Diagnosis of liver disease in children: value of MR angiography. AJR Am. J. Roentgenol. 159: 617-621 (1992). *

• Hughes MD, Raskino CL, Pocock SJ, Biagini MR, Burroughs AK. Prediction of short-term survival with an application in primary biliary cirrhosis. Stat. Med. 11: 1731-1745 (1992).

• Husby S, Oxelius VA, Svehag SE. IgG subclass antibodies to dietary antigens in IgA deficiency quantification and correlation with serum IgG subclass levels. Clin. Immunol. Immunopathol. 62: 85-90 (1992).

• Ibbotson JP, Lowes JR, Chahal H, Gaston JS, Life P, Kumararatne DS, Sharif H, Alexander-Williams J, Allan RN. Mucosal cell-mediated immunity to mycobacterial, enterobacterial and other microbial antigens in inflammatory bowel disease. Clin. Exp. Immunol. 87: 224-230 (1992). *

• Ilan Y, Shouval D. Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687 (1992).

• Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 103: 1587-1595 (1992).

• Isai H, Sheil AG, McCaughan G, Dolan P, Waugh R. Successful reversal of primary graft non-function in a liver transplant patient treated with prostaglandin E1. Aust. N.Z. J. Surg. 62: 314-316 (1992).

• Iwayama T, Leung PS, Rowley M, Munoz S, Nishioka M, Nakagawa T, Dickson ER, Coppel RL, Mackay IR, Gershwin ME. Comparative immunoreactive profiles of Japanese and American patients with primary biliary cirrhosis against mitochondrial autoantigens. Int. Arch. Allergy Immunol. 99: 28-33 (1992).

• Izzo RS, Witkon K, Chen AI, Hadjiyane C, Weinstein MI, Pellecchia C. Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am. J. Gastroenterol. 87: 1447-1452 (1992).

• Jagirdar J, Thung SN, Shah KD, Nudelman E, Singhal A, Paronetto F. Expression of sialylated Lewis(x) antigen in chronic and neoplastic liver diseases. Arch. Pathol. Lab. Med. 116: 643-648 (1992).

• Jahn HU, Zeitz M. Antibodies to neutrophilic granulocytes (p-ANCA): a further indication for a common origin of ulcerative colitis and primary sclerosing cholangitis? Z. Gastroenterol. 30: 441-442 (1992).

• Jankowski J, Crombie I, Jankowski R. Behcet's syndrome in Scotland. Postgrad. Med. J. 68: 566-570 (1992). *

• Jansen PL. Antifibrotic therapy of liver cirrhosis, with special reference to primary biliary cirrhosis: promises and limitations. Neth. J. Med. 40: 209-214 (1992).

• Jansen PL, Sanders JB. Primary sclerosing cholangitis. An unresolved enigma. Scand. J. Gastroenterol. Suppl. 194: 76-81 (1992).

• Javitt NB. Ursodeoxycholic acid therapy: the baby and the bathwater. Hosp. Pract. (Off. Ed.) 27: 12, 15-16 (1992).

• Joachim G, Hassall E. Familial inflammatory bowel disease in a paediatric population. J. Adv. Nurs. 17: 1310-1316 (1992).

• Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern. Med. 117: 297-302 (1992).

• Joplin R, Lindsay JG, Johnson GD, Strain A, Neuberger J. Membrane dihydrolipoamide acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis. Lancet 339: 93-94 (1992).

• Kagnoff MF. Celiac disease. A gastrointestinal disease with environmental, genetic, and immunologic components. Gastroenterol. Clin. North Am. 21: 405-425 (1992).

• Kahn E, Markowitz J, Daum F. The appendix in inflammatory bowel disease in children. Mod. Pathol. 5: 380-383 (1992).

• Kahn MF, Bouchon JP, Chamot AM, Palazzo E. Chronic enterocolopathies and SAPHO syndrome. 8 cases. Rev. Rhum. Mal. Osteoartic. 59: 91-94 (1992).

• Kakimoto H, Kawata S, Imai Y, Inada M, Matsuzawa Y, Tarui S. Changes in lipid composition of erythrocyte membranes with administration of S-adenosyl-L-methionine in chronic liver disease. Gastroenterol. Jpn. 27: 508-513 (1992).

• Kallenberg CG, Mulder AH, Tervaert JW. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am. J. Med. 93: 675-682 (1992).

• Kanai S, Sato Y, Kitani K. The effect of age on the biliary transport maximum (Tm) of bile salts in rats. Arch. Gerontol. Geriatr. 14: 101-115 (1992).

• Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J. Bezafibrate induced rhabdomyolysis. Ann. Rheum. Dis. 51: 536-538 (1992). *

• Kaplan MM, Knox TA. Methotrexate for primary biliary cirrhosis. Gastroenterology 102: 1824 (1992).

• Katschinski T, Galanos C, Coumbos A, Freudenberg MA. Gamma interferon mediates Propionibacterium acnes-induced hypersensitivity to lipopolysaccharide in mice. Infect. Immun. 60: 1994-2001 (1992). *

• Kaufmann SH. Heat shock proteins in health and disease. Int. J. Clin. Lab. Res. 21: 221-226 (1992).

• Kawano H, Abe M, Zhang D, Saikawa T, Fujimori M, Hirose S, Shirai T. Heterozygosity of the major histocompatibility complex controls the autoimmune disease in (NZW x BXSB) F1 mice. Clin. Immunol. Immunopathol. 65: 308-314 (1992).

• Keogan MT, Esnault VL, Green AJ, Lockwood CM, Brown DL. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin. Exp. Immunol. 90: 228-234 (1992). *

• Khan MA, Kellner H. Immunogenetics of spondyloarthropathies. Rheum. Dis. Clin. North Am. 18: 837-864 (1992).

• Kihira K, Mikami T, Ikawa S, Okamoto A, Yoshii M, Miki S, Mosbach EH, Hoshita T. Synthesis of sulfonate analogs of bile acids. Steroids 57: 193-198 (1992).

• Kim CI, Leo MA, Lieber CS. Retinol forms retinoic acid via retinal. Arch. Biochem. Biophys. 294: 388-393 (1992).

• Kim HS, Berstad A. Experimental colitis in animal models. Scand. J. Gastroenterol. 27: 529-537 (1992).

• Klaasen HL, Koopman JP, Poelma FG, Beynen AC. Intestinal, segmented, filamentous bacteria. FEMS Microbiol. Rev. 8: 165-180 (1992).

• Klausen T, Amris K, Helin P. Ulcerative colitis complicating seronegative HLA-A2-B27 rheumatoid arthritis with sacroiliitis. Ann. Rheum. Dis. 51: 1009-1011 (1992). *

• Kliewer SA, Umesono K, Heyman RA, Mangelsdorf DJ, Dyck JA, Evans RM. Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling. Proc. Natl. Acad. Sci. U.S.A. 89: 1448-1452 (1992). *

• Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355: 446-449 (1992). *

• Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774 (1992). *

• Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 102: 310-313 (1992).

• Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, de Vries RA, Brandt KH. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth. J. Med. 41: 11-16 (1992).

• Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 103: 840-847 (1992).

• Kondo N, Motoyoshi F, Mori S, Kuwabara N, Orii T, German J. Long-term study of the immunodeficiency of Bloom's syndrome. Acta Paediatr. 81: 86-90 (1992).

• Koskinas J, Portmann B, Lombard M, Smith T, Williams R. Persistent iron overload 4 years after inadvertent transplantation of a haemochromatotic liver in a patient with primary biliary cirrhosis. J. Hepatol. 16: 351-354 (1992).

• Kotz CM, Peterson LR, Moody JA, Savaiano DA, Levitt MD. Effect of yogurt on clindamycin-induced Clostridium difficile colitis in hamsters. Dig. Dis. Sci. 37: 129-132 (1992).

• Krahenbuhl S, Krahenbuhl-Glauser S, Stucki J, Gehr P, Reichen J. Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. Hepatology 15: 1167-1172 (1992).

• Krahenbuhl S, Reichen J. Adaptation of mitochondrial metabolism in liver cirrhosis. Different strategies to maintain a vital function. Scand. J. Gastroenterol. Suppl. 193: 90-96 (1992).

• Krahenbuhl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 15: 1160-1166 (1992).

• Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 175: 495-502 (1992). *

• Krzanowski JJ. Human major histocompatibility complex. Genes and diseases. J. Fla. Med. Assoc. 79: 97-99 (1992).

• Kuipers JG, Ehrfeld H, Hammer M, Zeidler H, Schmidt RE. Coincidence of a primary sclerosing cholangitis with an undifferentiated autoimmune disease. Immun. Infekt. 20: 64-65 (1992).

• Laajam MA, al-Mofarreh MA, al-Zayyani NR. Primary sclerosing cholangitis in chronic ulcerative colitis: report of cases in Arabs and review. Trop. Gastroenterol. 13: 106-111 (1992).

• Lahesmaa R, Skurnik M, Granfors K, Mottonen T, Saario R, Toivanen A, Toivanen P. Molecular mimicry in the pathogenesis of spondyloarthropathies. A critical appraisal of cross-reactivity between microbial antigens and HLA-B27. Br. J. Rheumatol. 31: 221-229 (1992).

• Lahteenmaki A, Hockerstedt K, Kajaste S, Huttunen M. Quality of life before and after liver transplantation: experiences with 7 patients with primary biliary cirrhosis in a 2-year follow-up. Transpl. Int. 5 Suppl. 1: S705-S707 (1992).

• Laitt RD, Hubscher SG, Buckels JA, Darby S, Elias E. Sclerosing cholangitis associated with multifocal fibrosis: a case report. Gut 33: 1430-1432 (1992). *

• Lang P, Klein R, Becker EW, Berg PA. Distribution of the PBC-specific-(M2) and the naturally-occurring mitochondrial antigen-(NOMAg) systems in plants. Clin. Exp. Immunol. 90: 509-516 (1992). *

• Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 103: 1444-1451 (1992).

• Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 117: 129-132 (1992).

• Lashner BA. Risk factors for small bowel cancer in Crohn's disease. Dig. Dis. Sci. 37: 1179-1184 (1992).

• Lauchart W. The status of liver transplantation 1992. Schweiz. Rundsch. Med. Prax. 81: 985-987 (1992).

• Lavo B, Knutson F, Knutson L, Sjoberg O, Hallgren R. Jejunal secretion of secretory immunoglobulins and gliadin antibodies in celiac disease. Dig. Dis. Sci. 37: 53-59 (1992).

• Lebovics E, Salama M, Elhosseiny A, Rosenthal WS. Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis. Gastroenterology 102: 2143-2147 (1992).

• Lee G, Shamma FN, Diamond MP, Lee JT. HLA-DQ beta 57 in Hispanic patients with insulin-dependent diabetes mellitus. Am. J. Obstet. Gynecol. 167: 1565-1570 (1992).

• Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J. Autoimmun. 5: 675-690 (1992).

• Leo MA, Kim C, Lowe N, Lieber CS. Interaction of ethanol with beta-carotene: delayed blood clearance and enhanced hepatotoxicity. Hepatology 15: 883-891 (1992).

• Leung PS, Iwayama T, Prindiville T, Chuang DT, Ansari AA, Wynn RM, Dickson R, Coppel R, Gershwin ME. Use of designer recombinant mitochondrial antigens in the diagnosis of primary biliary cirrhosis. Hepatology 15: 367-372 (1992).

• Leung PS, Krams S, Munoz S, Surh CP, Ansari A, Kenny T, Robbins DL, Fung J, Starzl TE, Maddrey W. Characterization and epitope mapping of human monoclonal antibodies to PDC-E2, the immunodominant autoantigen of primary biliary cirrhosis. J. Autoimmun. 5: 703-718 (1992).

• Leuschner U. Oral bile acid treatment of biliary cholesterol stones. Recenti Prog. Med. 83: 392-399 (1992).

• Leuschner U. Drug therapy of gallstone disease. Schweiz. Rundsch. Med. Prax. 81: 905-906 (1992).

• Leuschner U. Drug therapy of cholestatic hepatopathies. Schweiz. Rundsch. Med. Prax. 81: 983-984 (1992).

• Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, et al. 9-cis Retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 355: 359-361 (1992). *

• Levin B. Ulcerative colitis and colon cancer: biology and surveillance. J. Cell Biochem. Suppl. 16G: 47-50 (1992).

• Levine DS, Fischer SH, Christie DL, Haggitt RC, Ochs HD. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am. J. Gastroenterol. 87: 91-100 (1992).

• Levine J. Exogenous factors in Crohn's disease. A critical review. J. Clin. Gastroenterol. 14: 216-226 (1992).

• Li ZG, Waye JS, Chang PL. Diagnosis of arylsulfatase A deficiency. Am. J. Med. Genet. 43: 976-982 (1992).

• Liblau RS, Bach JF. Selective IgA deficiency and autoimmunity. Int. Arch. Allergy Immunol. 99: 16-27 (1992).

• Liblau RS, Caillat-Zucman S, Fischer AM, Bach JF, Boitard C. The prevalence of selective IgA deficiency in type 1 diabetes mellitus. APMIS 100: 709-712 (1992).

• Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J. Clin. Invest. 90: 1313-1322 (1992). *

• Liechti-Gallati S, Bonsall I, Malik N, Schneider V, Kraemer LG, Ruedeberg A, Moser H, Kraemer R. Genotype/phenotype association in cystic fibrosis: analyses of the delta F508, R553X, and 3905insT mutations. Pediatr. Res. 32: 175-178 (1992).

• Lillemoe KD, Pitt HA, Cameron JL. Current management of benign bile duct strictures. Adv. Surg. 25: 119-174 (1992).

• Lindberg E, Magnusson KE, Tysk C, Jarnerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 33: 909-913 (1992). *

• Lindberg MC. Hepatobiliary complications of oral contraceptives. J. Gen. Intern. Med. 7: 199-209 (1992).

• Lindgren S, Danielsson A, Olsson R, Prytz H, Eriksson S. Prednimustin treatment in primary biliary cirrhosis: a preliminary study. J. Intern. Med. 231: 139-141 (1992).

• Lindor K. What is the role of major histocompatibility complex expression in cholestasis? Gastroenterology 102: 1429-1430 (1992).

• Lindor KD, Fleming CR, Burnes JU, Nelson JK, Ilstrup DM. A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin. Proc. 67: 328-333 (1992).

• Linn FV, Peppercorn MA. Drug therapy for inflammatory bowel disease: part II. Am. J. Surg. 164: 178-185 (1992).

• Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795 (1992). *

• Lirussi F, Okolicsanyi L. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease. Ital. J. Gastroenterol. 24: 31-35 (1992).

• Lo SK, Fleming KA, Chapman RW. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 33: 1370-1375 (1992). *

• Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin. Exp. Immunol. 88: 45-49 (1992). *

• Lohse AW, Reckmann A, Kyriatsoulis A, Gerken G, Meyer zum Buschenfelde KH, Manns M. In vitro secretion of specific antimitochondrial antibodies in primary biliary cirrhosis. J. Hepatol. 16: 165-170 (1992).

• Lu Y, Kim BS, Pope RM. Clonal heterogeneity of synovial fluid T lymphocytes in inflammatory synovitis. Clin. Immunol. Immunopathol. 63: 28-33 (1992).

• Ludwig J, Wahlstrom HE, Batts KP, Wiesner RH. Papillary bile duct dysplasia in primary sclerosing cholangitis. Gastroenterology 102: 2134-2138 (1992).

• Lyttkens K, Prytz H, Forsberg L, Hederstrom E, Hagerstrand I. Ultrasound, hepatic lymph nodes and primary biliary cirrhosis. J. Hepatol. 15: 136-139 (1992).

• Mackay CR, Marston WL, Dudler L, Spertini O, Tedder TF, Hein WR. Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. Eur. J. Immunol. 22: 887-895 (1992).

• Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 268: 1578-1580 (1992).

• Macpherson AJ, Chester KA, Robson L, Bjarnason I, Malcolm AD, Peters TJ. Increased expression of c-myc proto-oncogene in biopsies of ulcerative colitis and Crohn's colitis. Gut 33: 651-656 (1992). *

• Macpherson AJ, Mayall TP, Chester KA, Abbasi A, Forgacs I, Malcolm AD, Peters TJ. Mitochondrial gene expression in the human gastrointestinal tract. J. Cell Sci. 102: 307-314 (1992). *

• Madsen JR, Laursen LS, Lauritsen K. Chronic inflammatory bowel disease - current status. Ugeskr. Laeger. 154: 2243-2250 (1992).

• Maeda T, Onishi S, Saibara T, Iwasaki S, Yamamoto Y. HLA DRw8 and primary biliary cirrhosis. Gastroenterology 103: 1118-1119 (1992).

• Maekawa S, Yano E, Shintani S. A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies. Ryumachi. 32: 515-521 (1992).

• Magliocca FM, Bonamico M, Petrozza V, Correr S, Montuori M, Triglione P, Carpino F. Scanning electron microscopy of the small intestine during gluten-challenge in celiac disease. Arch. Histol. Cytol. 55: S125-S130 (1992).

• Mahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ. Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin. Sci. (Lond.) 82: 273-275 (1992).

• Mahran MZ, Ross DG, Sadeghi-Nejad A, Rabson AR. Use of the polymerase chain reaction mismatch technique to identify the HLA-DQw8 allele in patients with insulin-dependent diabetes mellitus. Am. J. Clin. Pathol. 97: 29-33 (1992).

• Maksymowych WP, Gabriel CA, Luyrink L, Melin-Aldana H, Elma M, Giannini EH, Lovell DJ, Van Kerckhove C, Leiden J, Choi E, et al. Polymorphism in a T-cell receptor variable gene is associated with susceptibility to a juvenile rheumatoid arthritis subset. Immunogenetics 35: 257-262 (1992).

• Malhotra U, Concannon P. T cell receptor beta gene polymorphism and rheumatoid arthritis. Autoimmunity 12: 75-77 (1992).

• Malleson PN, Fung MY, Petty RE, Mackinnon MJ, Schroeder ML. Autoantibodies in chronic arthritis of childhood: relations with each other and with histocompatibility antigens. Ann. Rheum. Dis. 51: 1301-1306 (1992). *

• Mallett RB, Coulson IH, Holden CA. Acquired eruptive haemangiomata with primary biliary cirrhosis and prostatic carcinoma. Clin. Exp. Dermatol. 17: 206-207 (1992).

• Mallick BK. Primary sclerosing cholangitis. J. Assoc. Physicians India 40: 412-413 (1992).

• Mandera M, Nowakowska-Dulawa E, Hartleb M. Primary sclerosing cholangitis and primary biliary liver cirrhosis as the causes of intrahepatic cholestasis. Wiad. Lek. 45: 366-370 (1992).

• Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A, Evans RM. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev. 6: 329-344 (1992). *

• Manns MP. Autoimmune diseases of the liver. Clin. Lab. Med. 12: 25-40 (1992).

• Mantovani V, Corazza GR, Frisoni M, Zaniboni MG, Bragliani M, Valentini RA, Barboni P, Lambertini A, Gasbarrini G. HLA-DP polymorphism in northern Italian celiac patients. Tissue Antigens 40: 182-186 (1992).

• Manzano L, Alvarez-Mon M, Abreu L, Antonio Vargas J, de la Morena E, Corugedo F, Durantez A. Functional impairment of natural killer cells in active ulcerative colitis: reversion of the defective natural killer activity by interleukin 2. Gut 33: 246-251 (1992). *

• Marinaccio M, Pinto V, Sambati GS, Papandrea D, De Veteris M. Uncomplicated pregnancy in patients with unrecognized primary biliary cirrhosis. Minerva Ginecol. 44: 273-276 (1992).

• Martin FM, Braasch JW. Primary sclerosing cholangitis Curr. Probl. Surg. 29: 133-193 (1992).

• Matiushin BN, Loginov AS, Tkachev VD. Antioxidant liver enzymes in chronic liver disease. Patol. Fiziol. Eksp. Ter. 2: 41-42 (1992).

• Mattila J, Pitkanen R, Halonen P, Matikainen M. Ultrastructural aspects of liver injury with special reference to small bile ducts in patients with ulcerative colitis. Liver 12: 155-160 (1992).

• Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am. J. Gastroenterol. 87: 176-181 (1992).

• McDonald JA, Snitch P, Painter D, Hensley W, Gallagher ND, McCaughan GW. Striking variability of hepatic copper levels in fulminant hepatic failure. J. Gastroenterol. Hepatol. 7: 396-398 (1992).

• McFadden J, Collins J, Beaman B, Arthur M, Gitnick G. Mycobacteria in Crohn's disease: DNA probes identify the wood pigeon strain of Mycobacterium avium and Mycobacterium paratuberculosis from human tissue. J. Clin. Microbiol. 30: 3070-3073 (1992). *

• McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am. J. Med. 92: 254-256 (1992).

• McMenemy A. Whipple's disease, familial Mediterranean fever, adult-onset Still's disease, and enteropathic arthritis. Curr. Opin. Rheumatol. 4: 479-483 (1992).

• Mega J, Fujihashi K, Kiyono H. Regulation of mucosal immune responses by T lymphocytes: the effect of chronic CD4+ T cell deficiency on IgA synthesis. Reg. Immunol. 4: 70-78 (1992).

• Mehal WZ, Hattersley AT, Chapman RW, Fleming KA. A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assay. J. Hepatol. 15: 396-399 (1992).

• Mendez Sanchez N, Cote C, Aguilar Ramirez A, Uribe M. Physico-chemical properties of ursodeoxycholic acid and its usefulness in hepatopathies. Rev. Gastroenterol. Mex. 57: 183-190 (1992).

• Menendez JL, Giron JA, Manzano L, Garrido A, Abreu L, Albillos A, Durantez A, Alvarez-Mon M. Deficient interleukin-2 responsiveness of T lymphocytes from patients with primary biliary cirrhosis. Hepatology 16: 931-936 (1992).

• Mentha G, Huber O, Le Coultre C, Widmann JJ, Meyer P, Klopfenstein C, Morel P, Suter P, Rohner A. Liver transplantation for primary biliary cirrhosis. Schweiz. Med. Wochenschr. 122: 648-651 (1992).

• Mentha G, Wesolowski R, Rohner A. Who are the candidates for liver transplantation? Ther. Umsch. 49: 358-363 (1992).

• Merkel C, Bolognesi M, Bellon S, Sacerdoti D, Bianco S, Amodio P, Gatta A. Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. J. Hepatol. 15: 299-303 (1992).

• Middleton D, Savage DA, Cullen C, Trainor F, Mallon E, Hawkins S. Frequency of HLA-DPB1 alleles in multiple sclerosis patients from Northern Ireland. Eur. J. Immunogenet. 19: 323-326 (1992).

• Miller LC, Kaplan MM. Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am. J. Gastroenterol. 87: 465-470 (1992).

• Misbah SA, Spickett GP, Zeman A, Esiri MM, Wallington TB, Kurtz JB, Chapel HM. Progressive multifocal leucoencephalopathy, sclerosing cholangitis, bronchiectasis and disseminated warts in a patient with primary combined immune deficiency. J. Clin. Pathol. 45: 624-627 (1992).

• Mistry P, Seymour CA. Primary biliary cirrhosis - from Thomas Addison to the 1990s. Q. J. Med. 82: 185-196 (1992).

• Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J. Hepatol. 15: 336-344 (1992).

• Mizuki N, Inoko H, Mizuki N, Tanaka H, Kera J, Tsuiji K, Ohno S. Human leukocyte antigen serologic and DNA typing of Behcet's disease and its primary association with B51. Invest. Ophthalmol. Vis. Sci. 33: 3332-3340 (1992). *

• Mizuki N, Inoko H, Sugimura K, Nishimura K, Nakamura S, Tanaka H, Mizuki N, Mizuki H, Inaba G, Tsuji K, et al. RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Behcet's disease. Invest. Ophthalmol. Vis. Sci. 33: 3084-3090 (1992). *

• Mizuki N, Ohno S, Tanaka H, Sugimura K, Seki T, Mizuki N, Kera J, Inaba G, Tsuji K, Inoko H. Association of HLA-B51 and lack of association of class II alleles with Behcet's disease. Tissue Antigens 40: 22-30 (1992).

• Moragas A, Allende H, Sans M, Vidal MT, Garcia-Bonafe M, Huguet P. Cirrhotic changes in livers from children undergoing transplantation. Image analysis. Anal. Quant. Cytol. Histol. 14: 359-366 (1992).

• Morito F, Hiida M, Ohta A, Yamaguchi M. Genetic analysis of systemic lupus erythematosus: association with a T cell receptor restriction fragment length polymorphism in Japanese patients. Intern. Med. 31: 998-1003 (1992). *

• Moriuchi J, Ichikawa Y, Takaya M, Shimizu H, Uchiyama M, Inoko H, Tsuji K, Arimori S. Lack of deletion of complement C4 and steroid 21-hydroxylase genes in Japanese patients with primary Sjogren's syndrome. J. Rheumatol. 19: 700-703 (1992).

• Morling N, Dalhoff K, Fugger L, Georgsen J, Jakobsen B, Ranek L, Odum N, Svejgaard A. DNA polymorphism of HLA class II genes in primary biliary cirrhosis. Immunogenetics 35: 112-116 (1992).

• Morshed SA, Nishioka M, Saito I, Komiyama K, Moro I. Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients. Gastroenterol. Jpn. 27: 751-758 (1992).

• Moss MT, Sanderson JD, Tizard ML, Hermon-Taylor J, el-Zaatari FA, Markesich DC, Graham DY. Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues. Gut 33: 1209-1213 (1992). *

• Moss RB, Carmack MA, Esrig S. Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. J. Pediatr. 120: 16-21 (1992).

• Moutsopoulos HM, Papadopoulos GK. Possible viral implication in the pathogenesis of Sjogren's syndrome. Eur. J. Med. 1: 219-223 (1992).

• Mowat AP. Orthotopic liver transplantation in liver-based metabolic disorders. Eur. J. Pediatr. 151 Suppl. 1: S32-S38 (1992).

• Mulder TP, Janssens AR, Verspaget HW, van Hattum J, Lamers CB. Metallothionein concentration in the liver of patients with Wilson's disease, primary biliary cirrhosis, and liver metastasis of colorectal cancer. J. Hepatol. 16: 346-350 (1992).

• Mulherin D, FitzGerald M. Cystic fibrosis in adolescents and adults. The coming of age of cystic fibrosis. Dig. Dis. 10: 29-37 (1992).

• Muller C, Zielinski CC. Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis. J. Hepatol. 15: 372-377 (1992).

• Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 102: 1620-1627 (1992).

• Munford RS, Hunter JP. Acyloxyacyl hydrolase, a leukocyte enzyme that deacylates bacterial lipopolysaccharides, has phospholipase, lysophospholipase, diacylglycerollipase, and acyltransferase activities in vitro. J. Biol. Chem. 267: 10116-10121 (1992). *

• Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 339: 381-385 (1992).

• Nagura H. Mucosal defense mechanism in health and disease. Role of the mucosal immune system. Acta Pathol. Jpn. 42: 387-400 (1992).

• Nakamura H, Yoshimura K, Bajocchi G, Trapnell BC, Pavirani A, Crystal RG. Tumor necrosis factor modulation of expression of the cystic fibrosis transmembrane conductance regulator gene. FEBS Lett. 314: 366-370 (1992). *

• Nakamura K, Aoshima M, Tani M, Kato T, Fugita M, Kimura A, Hasegawa T, Akiyama K, Makino I. Effect of ursodeoxycholic acid (UDCA) therapy for compensatory liver cirrhosis on liver function tests and serum bile acid metabolism. Nippon Shokakibyo Gakkai Zasshi 89: 2762-2770 (1992).

• Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut 33: 933-937 (1992). *

• Nakamura MC, Nakamura RM. Contemporary concepts of autoimmunity and autoimmune diseases. J. Clin. Lab. Anal. 6: 275-289 (1992).

• Nakamuta M, Sugimura T, Kotoh K, Fukutomi T, Sakamoto S, Yamamoto M, Nawata H. Anti-tolA antibody in non-A, non-B chronic liver disease. Fukuoka Igaku Zasshi 83: 367-376 (1992).

• Nakano T, Ishibashi H, Matsui M, Yasutake T, Ishii Y, Dohmen K, Nagasawa K, Niho Y. A case of primary biliary cirrhosis with negative anti-mitochondrial antibody anteceded by rheumatoid arthritis. Fukuoka Igaku Zasshi 83: 144-148 (1992).

• Nakato T, Fukushima M, Yamamoto H. Anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel diseases (IBD). Gastroenterol. Jpn. 27: 683 (1992).

• Nakshabendi IM, Duncan A, Russell RI. Is asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis? Postgrad. Med. J. 68: 189-191 (1992). *

• Nattermann C, Goldschmidt AJ, Dancygier H. Endosonography in chronic pancreatitis. A comparative study of endoscopic retrograde pancreatography and endoscopic sonography. Ultraschall. Med. 13: 263-270 (1992).

• Neundorfer B. Neurologic concomitant diseases in Crohn disease. Fortschr. Neurol. Psychiatr. 60: 481-486 (1992).

• Nielsen OH, Ahnfelt-Ronne I. Significance of free oxygen radicals for pathogenesis of chronic inflammatory disease. Ugeskr. Laeger. 154: 2544-2546 (1992).

• Nikkila K. Liver transplantation restores low serum levels of very low density and high density lipoproteins in end-stage primary biliary cirrhosis. Ann. Med. 24: 129-136 (1992).

• Nikkila K, Hockerstedt K, Miettinen TA. Serum and hepatic cholestanol, squalene and noncholesterol sterols in man: a study on liver transplantation. Hepatology 15: 863-870 (1992).

• Nikkila K, Hockerstedt K, Miettinen TA. Liver transplantation modifies serum cholestanol, cholesterol precursor and plant sterol levels. Clin. Chim. Acta 208: 205-218 (1992).

• Nilssen DE, Brandtzaeg P, Froland SS, Fausa O. Subclass composition and J-chain expression of the 'compensatory' gastrointestinal IgG cell population in selective IgA deficiency. Clin. Exp. Immunol. 87: 237-245 (1992). *

• Noble J, Arafa M, Royle SG, McGeorge G, Crank S. The association between alcohol, hepatic pathology and Dupuytren's disease. J. Hand Surg. [Br.] 17: 71-74 (1992).

• Noguchi H, Kephart GM, Colby TV, Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am. J. Pathol. 140: 521-528 (1992).

• Noguchi K, Kobayashi M, Yagihashi A, Yoshida Y, Terasawa K, Konno A, Ichida F, Venek M, Iwatsuki S, Starzl TE, et al. HLA antigens in primary sclerosing cholangitis. Transplant. Proc. 24: 2775-2776 (1992).

• Noh LM, Low SM, Lajin I, Abdullah N. Antibody deficiency with hyper IgM - a case report. Malays. J. Pathol. 14: 121-123 (1992).

• Norman AW. Identification of a unique nuclear receptor for 9-cis retinoic acid. Nutr. Rev. 50: 230-231 (1992).

• Novotny DA, Rubin RJ, Slezak FA, Porter JA. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis. Colon Rectum 35: 193-196 (1992).

• Nyberg A, Lindqvist U, Engstrom-Laurent A. Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome. J. Intern. Med. 231: 485-491 (1992).

• O'Brien S, Keogan M, Casey M, Duffy G, McErlean D, Fitzgerald MX, Hegarty JE. Biliary complications of cystic fibrosis. Gut 33: 387-391 (1992). *

• Obayashi M, Matsui-Yuasa I, Matsumoto T, Kitano A, Kobayashi K, Otani S. Polyamine metabolism in colonic mucosa from patients with ulcerative colitis. Am. J. Gastroenterol. 87: 736-740 (1992).

• Ohhira M, Ono M, Ohhira M, Tsukadaira T, Matsumoto A, Ohta H, Mima S, Sekiya C, Namiki M. Primary biliary cirrhosis and manganese-superoxide dismutase. Nippon Shokakibyo Gakkai Zasshi 89: 1474 (1992).

• Olausson M, Mjornstedt L, Wramner L, Persson H, Karlberg I, Friman S. Adjuvant treatment with ursodeoxycholic acid prevents acute rejection in rats receiving heart allografts. Transpl. Int. 5 Suppl. 1: S539-S541 (1992).

• Olerup O, Smith CI, Bjorkander J, Hammarstrom L. Shared HLA class II-associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiency. Proc. Natl. Acad. Sci. U.S.A. 89: 10653-10657 (1992). *

• Ollier W, Thomson W. Population genetics of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 18: 741-759 (1992).

• Olsson PG, Hammarstrom L, Cox DW, Smith CI. Involvement of both HLA and Ig heavy chain haplotypes in human IgA deficiency. Immunogenetics 36: 389-395 (1992).

• Oren R, Ilan Y. Reversible hepatic injury induced by long-term vitamin A ingestion. Am. J. Med. 93: 703-704 (1992).

• Oritani K, Kaisho T, Nakajima K, Hirano T. Retinoic acid inhibits interleukin-6-induced macrophage differentiation and apoptosis in a murine hematopoietic cell line, Y6. Blood 80: 2298-2305 (1992).

• Ostedgaard LS, Shasby DM, Welsh MJ. Staphylococcus aureus alpha-toxin permeabilizes the basolateral membrane of a Cl(-)-secreting epithelium. Am. J. Physiol. 263: L104-L112 (1992).

• Ostedgaard LS, Welsh MJ. Partial purification of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 267: 26142-26149 (1992). *

• Ota M, Seki T, Kiyosawa K, Furuta S, Hino K, Kondo T, Fukushima H, Tsuji K, Inoko H. A possible association between basic amino acids of position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics 36: 49-55 (1992).

• Outschoorn IM, Natta CL. IgG subclass alterations in adult asthma. Microbiol. Immunol. 36: 977-982 (1992).

• Outwater E, Kaplan MM, Bankoff MS. Lymphadenopathy in sclerosing cholangitis: pitfall in the diagnosis of malignant biliary obstruction. Gastrointest. Radiol. 17: 157-160 (1992). *

• Padbury RT, Gunson BK, Dousset B, Hubscher SG, Mayer AD, Buckels JA, Neuberger JM, Elias E, McMaster P. Long-term immunosuppression after liver transplantation: are steroids necessary? Transpl. Int. 5 Suppl. 1: S470-S472 (1992).

• Pallone F, Fais S, Capobianchi MR. Evidence against an autoimmune aetiology for inflammatory bowel diseases. Gut 33: 1008 (1992). *

• Papiha SS, Murty GE, Ad'Hia A, Mains BT, Venning M. Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann. Rheum. Dis. 51: 246-248 (1992). *

• Pawlotsky JM, Andre C, Metreau JM, Beaugrand M, Zafrani ES, Dhumeaux D. Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis. Hepatology 16: 127-131 (1992).

• Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J. Hepatol. 14: 325-331 (1992).

• Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology 102: 1389-1391 (1992).

• Petkovich M. Regulation of gene expression by vitamin A: the role of nuclear retinoic acid receptors. Annu. Rev. Nutr. 12: 443-471 (1992). *

• Pezzana A, Boggio Bertinet D, Costantino AM, Da Pont MC, Pera A. Possibilities and limitations of nutritional support in Crohn disease. Minerva Gastroenterol. Dietol. 38: 161-165 (1992).

• Phillips WG. Pruritus. What to do when the itching won't stop. Postgrad. Med. 92: 34-6, 39-40, 43-46 (1992).

• Philpot HC, Elewski BE, Banwell JG, Gramlich T. Pyostomatitis vegetans and primary sclerosing cholangitis: markers of inflammatory bowel disease. Gastroenterology 103: 668-674 (1992).

• Pietrzyk JJ, Turowski G, Kapinska-Mrowka M, Rozanski B. Family studies in psoriasis. I. Complex segregation analysis. Arch. Dermatol. Res. 273: 287-294 (1992).

• Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Montbrun T, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. Dig. Dis. Sci. 37: 1396-1403 (1992).

• Pile KD, Wordsworth BP, Bell JI. Does the locus on chromosome 11 implicated in susceptibility to HLA-DR4 dependent type I diabetes mellitus also affect susceptibility to rheumatoid arthritis? Ann. Rheum. Dis. 51: 1250-1251 (1992). *

• Pill J, Volkl A, Hartig F, Fahimi HD. Differences in the response of Sprague-Dawley and Lewis rats to bezafibrate: the hypolipidemic effect and the induction of peroxisomal enzymes. Arch. Toxicol. 66: 327-333 (1992).

• Pitkanen OM. Peroxidation of lipid emulsions: a hazard for the premature infant receiving parenteral nutrition? Free Radic. Biol. Med. 13: 239-245 (1992).

• Plaut AG, Ridker P. New light on secretory-component deficiency. N. Engl. J. Med. 327: 129 (1992).

• Pokorny CS, McCaughan GW, Gallagher ND, Selby WS. Sclerosing cholangitis and biliary tract calculi - primary or secondary? Gut 33: 1376-1380 (1992). *

• Polliack A, Lugassy G. Autoimmunity and auto-immune syndromes associated with and preceding the development of lymphoproliferative disorders. Leukemia 6 Suppl. 4: 152-154 (1992).

• Pontecorvo MJ, Levinson JD, Roth JA. A patient with primary biliary cirrhosis and multiple sclerosis. Am. J. Med. 92: 433-436 (1992).

• Poo JL, Feldmann G, Erlinger S, Braillon A, Gaudin C, Dumont M, Lebrec D. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 102: 1752-1759 (1992).

• Poupon RE, Poupon R. Ursodeoxycholic acid for the treatment of cholestatic diseases. Prog. Liver Dis. 10: 219-238 (1992).

• Pronai L, Yukinobu I, Lang I, Feher J. The oxygen-centered radicals scavenging activity of sulfasalazine and its metabolites. A direct protection of the bowel. Acta Physiol. Hung. 80: 317-323 (1992).

• Punchard NA, Boswell DJ, Greenfield SM, Thompson RP. The effects of sulphasalazine and its metabolites on prostaglandin production by human mononuclear cells. Biochem. Pharmacol. 43: 2369-2376 (1992).

• Punchard NA, Greenfield SM, Thompson RP. Mechanism of action of 5-aminosalicylic acid. Mediators Inflamm. 1: 151-165 (1992). *

• Purrmann J, Arendt G, Cleveland S, Borchard F, Furst W, Gemsa R, Bertrams J, Hengels KJ. Association of Crohn's disease and multiple sclerosis. Is there a common background? J. Clin. Gastroenterol. 14: 43-46 (1992).

• Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig. Dis. Sci. 37: 1606-1611 (1992).

• Rabinovitz M, Gavaler JS, Kelly RH, Prieto M, Van Thiel DH. Lack of increase in heterozygous alpha 1-antitrypsin deficiency phenotypes among patients with hepatocellular and bile duct carcinoma. Hepatology 15: 407-410 (1992).

• Rabinovitz M, Prieto M, Gavaler JS, Van Thiel DH. Bacteriuria in patients with cirrhosis. J. Hepatol. 16: 73-76 (1992).

• Rachmilewitz D, Eliakim R, Simon P, Ligumsky M, Karmeli F. Cytokines and platelet-activating factor in human inflamed colonic mucosa. Agents Actions Spec. No: C32-C36 (1992).

• Radchenko VG, Mitrofanova TI, Serebriakova VI, Vinogradova GL. The efficacy of immunomodulating preparations in treating patients with chronic cholestatic liver diseases. Lik. Sprava. 11-12: 38-41 (1992).

• Radin DR, Johnson MB. Candida cholangitis in a diabetic woman. AJR Am. J. Roentgenol. 158: 1029-1030 (1992). *

• Radwan P, Slomka M, Skrzydlo-Radomanska B. Expression of HLA-DR antigens by colonic epithelium in ulcerative colitis. Pol. Arch. Med. Wewn. 87: 358-364 (1992).

• Raeder MG. The origin of and subcellular mechanisms causing pancreatic bicarbonate secretion. Gastroenterology 103: 1674-1684 (1992).

• Raedler A, Schreiber S. Is ulcerative colitis an autoimmune disease? Dtsch. Med. Wochenschr. 117: 1333-1338 (1992).

• Raedsch R, Stiehl A, Walker S, Scherrmann JM, Kommerell B. Combined ursodeoxycholic acid plus colchicine - treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study. Z. Gastroenterol. 30 Suppl. 1: 55-57 (1992).

• Rafique S, Guardascione M, Osman E, Burroughs AK, Owen JS. Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-L-methionine. Clin. Sci. (Lond.) 83: 353-356 (1992).

• Ramakrishna B, Chandy G. Primary biliary cirrhosis - a case report. Indian J. Pathol. Microbiol. 35: 153-156 (1992).

• Ramos C, Arazo P, Aguirre JM, Alvarez G, Aísa ML, Gonzalo C, Ferreria V. Sclerosing cholangitis and AIDS. Rev. Clin. Esp. 190: 79-81 (1992).

• Rand EB, Whitington PF. Successful orthotopic liver transplantation in two patients with liver failure due to sclerosing cholangitis with Langerhans cell histiocytosis. J. Pediatr. Gastroenterol. Nutr. 15: 202-207 (1992).

• Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions Spec. No.: C37-C46 (1992).

• Rasmussen HH, Fallingborg J, Mortensen PB, Freund L, Tage-Jensen U, Kruse V, Rasmussen SN. Primary sclerosing cholangitis in patients with ulcerative colitis. Scand. J. Gastroenterol. 27: 732-736 (1992).

• Rebora A, Robert E, Rongioletti F. Clinical and laboratory presentation of lichen planus patients with chronic liver disease. J. Dermatol. Sci. 4: 38-41 (1992).

• Reed JF 3rd, Calkins BM, Rosen L. Concordance of familial characteristics in Crohn's disease and ulcerative colitis. Dis. Colon Rectum 35: 405-410 (1992).

• Reichen J. Drug treatment of cholestatic liver diseases. Ther. Umsch. 49: 315-325 (1992).

• Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterol. Clin. North Am. 21: 905-921 (1992).

• Riether AM, Smith SL, Lewison BJ, Cotsonis GA, Epstein CM. Quality-of-life changes and psychiatric and neurocognitive outcome after heart and liver transplantation. Transplantation 54: 444-450 (1992).

• Riis P. Extension of indications of immunosuppression in inflammatory bowel disease. J. Autoimmun. 5 Suppl. A: 289-291 (1992).

• Rijk MC, van Schaik A, van Tongeren JH. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand. J. Gastroenterol. 27: 863-868 (1992).

• Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 47: 897-902 (1992). *

• Roediger WE, Kapaniris O, Millard S. Lipogenesis from n-butyrate in colonocytes. Action of reducing agent and 5-aminosalicylic acid with relevance to ulcerative colitis. Mol. Cell. Biochem. 118: 113-118 (1992).

• Roitt IM, Hutchings PR, Dawe KI, Sumar N, Bodman KB, Cooke A. The forces driving autoimmune disease. J. Autoimmun. 5 Suppl. A: 11-26 (1992).

• Roman SH, Greenberg D, Rubinstein P, Wallenstein S, Davies TF. Genetics of autoimmune thyroid disease: lack of evidence for linkage to HLA within families. J. Clin. Endocrinol. Metab. 74: 496-503 (1992).

• Romas E, Paspaliaris B, d'Apice AJ, Elliott PR. Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease. Aust. N. Z. J. Med. 22: 652-659 (1992).

• Rossi SO, Gilbert-Barness E, Saari T, Corliss R. Pulmonary hypertension with coexisting portal hypertension. Pediatr. Pathol. 12: 433-439 (1992).

• Rothuizen J, van den Brom WE, Fevery J. The origins and kinetics of bilirubin in dogs with hepatobiliary and haemolytic diseases. J. Hepatol. 15: 17-24 (1992).

• Rowley MJ, Maeda T, Mackay IR, Loveland BE, McMullen GL, Tribbick G, Bernard CC. Differing epitope selection of experimentally-induced and natural antibodies to a disease-specific autoantigen, the E2 subunit of pyruvate dehydrogenase complex (PDC-E2). Int. Immunol. 4: 1245-1253 (1992).

• Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103: 1611-1620 (1992).

• Ruiz Montes F, Rene Espinet JM, Rubio Caballero M. Eosinophilic gastroenteritis: review of the published cases in Spain and comparison with foreign literature. Rev. Esp. Enferm. Dig. 81: 270-279 (1992).

• Rump JA, Roth M, Scholmerich J, Helfesrieder R, Ludemann J, Gross WL, Rautmann A, Peter HH. A new type of ANCA in sera of patients with ulcerative colitis: effects of therapy and disease severity on serum titer. Immun. Infekt. 20: 16-18 (1992).

• Ruthlein J, Ibe M, Burghardt W, Mossner J, Auer IO. Immunoglobulin G (IgG), IgG1, and IgG2 determinations from endoscopic biopsy specimens in control, Crohn's disease, and ulcerative colitis subjects. Gut 33: 507-512 (1992). *

• Sabouraud A, Rochdi M, Urtizberea M, Christen MO, Achtert G, Scherrmann JM. Pharmacokinetics of colchicine: a review of experimental and clinical data. Z. Gastroenterol. 30 Suppl. 1: 35-39 (1992).

• Saclarides TJ, Jakate SM, Coon JS, Bhattacharyya AK, Dominguez JM, Szeluga DJ, Weinstein RS. Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis. Dis. Colon Rectum 35: 747-752 (1992).

• Sakanoue Y, Horai T, Okamoto T, Hatada T, Shoji Y, Fujita S, Kusunoki M, Utsunomiya J. Lipocortin-present perforating and lipocortin-absent nonperforating Crohn's disease. Am. J. Surg. 164: 341-344 (1992).

• Salazar Villa RM, Acosta Ortíz R, Mejía Ortega J, Martínez Cairo y Cueto S, Castro Ramos F, Villa Michel ER, Zambrano Villa SA. Symptomatic dermatographism and HLA antigens. Rev. Alerg. 39: 89-95 (1992).

• San Andres Rebollo FJ, Gonzalez Rubio M, Postigo C, Garfia C, Cabeza Alvarez CI, Viana Alonso A. Hypersensitivity syndrome caused by allopurinol: report of 2 cases and review of the literature. Rev. Clin. Esp. 191: 426-429 (1992).

• Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15: 215-221 (1992).

• Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin. Proc. 67: 981-990 (1992).

• Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 33: 890-896 (1992). *

• Sandler RS, Sandler DP, McDonnell CW, Wurzelmann JI. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis. Am. J. Epidemiol. 135: 603-608 (1992).

• Sauter G, Ruckdeschel G, Sauerbruch T. Antibiotic prevention and therapy of infectious complications in ERCP. Leber. Magen. Darm. 22: 173-176 (1992).

• Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am. J. Pathol. 141: 335-342 (1992). *

• Savage DA, Middleton D, Trainor F, Taylor A, Carson M, Stevens FM, McCarthy CF. HLA class II frequencies in celiac disease patients in the west of Ireland. Hum. Immunol. 34: 47-52 (1992).

• Saxon A, Sidell N, Zhang K. B cells from subjects with CVI can be driven to Ig production in response to CD40 stimulation. Cell. Immunol. 144: 169-181 (1992).

• Scarpa R, del Puente A, D'Arienzo A, di Girolamo C, della Valle G, Panarese A, Lubrano E, Oriente P. The arthritis of ulcerative colitis: clinical and genetic aspects. J. Rheumatol. 19: 373-377 (1992).

• Scheurlen M, Mork H, Weber P. Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis. J. Clin. Gastroenterol. 14: 59-63 (1992).

• Schlaghecke R, Kornely E, Wollenhaupt J, Specker C. Glucocorticoid receptors in rheumatoid arthritis. Arthritis Rheum. 35: 740-744 (1992).

• Schlenker T, Apenberg S, Raedsch R, Andrassy K, Plachky J, Kommerell B. Antineutrophil cytoplasmic antibodies in chronic inflammatory bowel diseases. Dtsch. Med. Wochenschr. 117: 1463-1468 (1992).

• Schlesinger M, Benbassat C, Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol. Res. 11: 98-103 (1992).

• Schrander-van der Meer AM, Vogten AJ. Estimation of survival probability in cirrhotics. Evaluation of a computer model applicable for decision-making. Neth. J. Med. 40: 183-189 (1992).

• Schreiber RA, Kleinman RE, Barksdale EM Jr, Maganaro TF, Donahoe PK. Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. Gastroenterology 102: 924-930 (1992).

• Schreiber S, Raedler A, Stenson WF, MacDermott RP. The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol. Clin. North Am. 21: 451-502 (1992).

• Schweizer M, Schweizer P, Knupfer R, Dietz K. Extrahepatic bile duct atresia. Comparison of surgical and non-surgical therapy. Monatsschr. Kinderheilkd. 140: 422-425 (1992).

• Seaward BL. Humor's healing potential. Health Prog. 73: 66-70 (1992).

• Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 33: 657-662 (1992). *

• Seifert G. Tumour-like lesions of the salivary glands. The new WHO classification. Pathol. Res. Pract. 188: 836-846 (1992).

• Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, Mizuki N, Ando A, Tsuji K, Inoko H, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 103: 1041-1047 (1992).

• Selve N, Wohrmann T. Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease. Mediators Inflamm. 1: 121-126 (1992). *

• Semana G. Genetic susceptibility of insulin-dependent diabetes. Ann. Endocrinol. (Paris) 53: 73-77 (1992).

• Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch. Dis. Child. 67: 1447-1453 (1992). *

• Seo JK, Yeon KM, Chi JG. Inflammatory bowel disease in children - clinical, endoscopic, radiologic and histopathologic investigation. J. Korean Med. Sci. 7: 221-235 (1992). *

• Serjeantson SW, Gao X, Hawkins BR, Higgins DA, Yu YL. Novel HLA-DR2-related haplotypes in Hong Kong Chinese implicate the DQB1*0602 allele in susceptibility to multiple sclerosis. Eur. J. Immunogenet. 19: 11-19 (1992).

• Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann. Surg. 215: 598-603 (1992). *

• Shefer S, Nguyen LB, Salen G, Ness GC, Chowdhary IR, Lerner S, Batta AK, Tint GS. Differing effects of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities and mRNA levels in the rat. J. Lipid Res. 33: 1193-1200 (1992). *

• Sheil AG, McCaughan GW, Thompson JF, Dorney SF, Stephen MS, Bookallil MJ. The first five years' clinical experience of the Australian National Liver Transplantation Unit. Med. J. Aust. 156: 9-16 (1992).

• Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J. Gastroenterol. Hepatol. 7: 277-282 (1992).

• Shin T, Mizoguchi Y, Kioka K, Kobayashi K, Morisawa S. Study on the mechanism of an experimental immunological intrahepatic cholestasis model. Osaka City Med. J. 38: 111-125 (1992).

• Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern. Med. 31: 1348-1355 (1992). *

• Siegert W, Stemerowicz R, Hopf U. Antimitochondrial antibodies in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 10: 221-227 (1992).

• Singal DP, Green D, Reid B, Gladman DD, Buchanan WW. HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA. Ann. Rheum. Dis. 51: 23-28 (1992). *

• Singer SS, Dravis D, Henkels K, Trulzsch DV. Fatty acid binding protein inhibits glycolithocholate sulfation. Biochem. Int. 27: 373-383 (1992).

• Singh SP, Upshaw Y, Abdullah T, Singh SR, Klebba PE. Structural relatedness of enteric bacterial porins assessed with monoclonal antibodies to Salmonella typhimurium OmpD and OmpC. J. Bacteriol. 174: 1965-1973 (1992). *

• Sjoberg K, Alm R, Eriksson S. Angiotensinogen in chronic liver disease. Scand. J. Clin. Lab. Invest. 52: 57-63 (1992).

• Skakun NP, Tabachuk OE. The comparative action of isoniazid, rifampicin and ethambutol on liver function. Eksp. Klin. Farmakol. 55: 45-47 (1992).

• Skarsvag S, Hansen KE, Holst A, Moen T. Distribution of HLA class II alleles among Scandinavian patients with systemic lupus erythematosus (SLE): an increased risk of SLE among non[DRB1*03,DQA1*0501,DQB1*0201] class II homozygotes? Tissue Antigens 40: 128-133 (1992).

• Slocum MM, Sittig KM, Specian RD, Deitch EA. Absence of intestinal bile promotes bacterial translocation. Am. Surg. 58: 305-310 (1992).

• Sokal EM, Mostin J, Buts JP. Liver metabolic zonation in rat biliary cirrhosis: distribution is reverse of that in toxic cirrhosis. Hepatology 15: 904-908 (1992).

• Sorrentino R, De Grazia U, Buzzetti R, Nistico L, Iannicola C, Costanzi S, Tosi R. An explanation for the neutral effect of DR2 on IDDM susceptibility in central Italy. Diabetes 41: 904-908 (1992).

• Spengler U, Moller A, Jung MC, Messer G, Zachoval R, Hoffmann RM, Eisenburg J, Paumgartner G, Riethmuller G, Weiss EH, et al. T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation. J. Hepatol. 15: 129-135 (1992).

• Stahl W, Schwarz W, Sundquist AR, Sies H. cis-trans Isomers of lycopene and beta-carotene in human serum and tissues. Arch. Biochem. Biophys. 294: 173-177 (1992).

• Stenson WF, Cort D, Rodgers J, Burakoff R, DeSchryver-Kecskemeti K, Gramlich TL, Beeken W. Dietary supplementation with fish oil in ulcerative colitis. Ann. Intern. Med. 116: 609-614 (1992).

• Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, Strom TB. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig. Dis. Sci. 37: 818-826 (1992).

• Stevens TR, Winrow VR, Blake DR, Rampton DS. Circulating antibodies to heat-shock protein 60 in Crohn's disease and ulcerative colitis. Clin. Exp. Immunol. 90: 271-274 (1992). *

• Stiehl A. Pathophysiology of cholestasis: correlation between bile acid metabolism and liver damage. Z. Gastroenterol. 30 Suppl. 1: 46-48 (1992).

• Stiehl A. Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid. Z. Gastroenterol. 30: 743-747 (1992).

• Storch W. Virus and autoimmune disease. An excursion exemplified by autoimmune hepatitis. Leber. Magen. Darm. 22: 5-9 (1992).

• Strober W, James SP. The immunopathogenesis of gastrointestinal and hepatobiliary diseases. JAMA 268: 2910-2917 (1992).

• Strong TV, Smit LS, Nasr S, Wood DL, Cole JL, Iannuzzi MC, Stern RC, Collins FS. Characterization of an intron 12 splice donor mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Hum. Mutat. 1: 380-387 (1992).

• Stronkhorst A, Tytgat GN, van Deventer SJ. CD4 antibody treatment in Crohn's disease. Scand. J. Gastroenterol. Suppl. 194: 61-65 (1992).

• Stuart D, Orelowitz J, Bank S, Stark B, Hilton E. Fungemia with Torulopsis glabrata after endoscopic biliary stent replacement. Am. J. Gastroenterol. 87: 883-885 (1992).

• Sturniolo GC, D'Inca R, Parisi G, Giacomazzi F, Montino MC, D'Odorico A, Soranzo P, Naccarato R. Taste alterations in liver cirrhosis: are they related to zinc deficiency? J. Trace Elem. Electrolytes Health Dis. 6: 15-19 (1992).

• Sutherland DE, Smith WA. Chemical hepatitis associated with occupational exposure to halothane in a research laboratory. Vet. Hum. Toxicol. 34: 423-424 (1992).

• Szewczuk MR, Depew WT. Evidence for T lymphocyte reactivity to the 65 kilodalton heat shock protein of mycobacterium in active Crohn's disease. Clin. Invest. Med. 15: 494-505 (1992).

• Szostecki C, Will H, Netter HJ, Guldner HH. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand. J. Immunol. 36: 555-564 (1992).

• Talal N, Flescher E, Dang H. Are endogenous retroviruses involved in human autoimmune disease? J. Autoimmun. 5 Suppl. A: 61-66 (1992).

• Tanaka H, Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 188: 942-948 (1992). *

• Tanner MS. Liver and biliary problems in cystic fibrosis. J. R. Soc. Med. 85 Suppl. 19: 20-24 (1992). *

• Teige B, Olaisen B, Teisberg P. Haptoglobin subtypes in Norway and a review of HP subtypes in various populations. Hum. Hered. 42: 93-106 (1992).

• Tervaert JW, Mulder AH, Horst G, Haagsma EB, Kleibeuker JH, Kallenberg CG. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis, ulcerative colitis, and autoimmune diseases. Gastroenterology 102: 1090-1091 (1992).

• Tezcan I, Ersoy F, Sanal O. IgG subclasses in symptomatic IgA deficiency. Turk. J. Pediatr. 34: 1-4 (1992).

• Thayer WR. The use of antimycobacterial agents in Crohn's disease. J. Clin. Gastroenterol. 15: 5-7 (1992).

• Theilmann L. Colchicine in toxic liver cirrhosis and primary biliary cirrhosis. Z. Gastroenterol. 30 Suppl. 1: 40-42 (1992).

• Theise ND, Schwartz M, Miller C, Thung SN. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. Hepatology 16: 949-955 (1992).

• Thorsby E, Ronningen KS. Role of HLA genes in predisposition to develop insulin-dependent diabetes mellitus. Ann. Med. 24: 523-531 (1992).

• Thuluvath PJ, Triger DR. Selenium in chronic liver disease. J. Hepatol. 14: 176-182 (1992).

• Tienari PJ, Wikstrom J, Sajantila A, Palo J, Peltonen L. Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene. Lancet 340: 987-991 (1992).

• Tighe MR, Hall MA, Barbado M, Cardi E, Welsh KI, Ciclitira PJ. HLA class II alleles associated with celiac disease susceptibility in a southern European population. Tissue Antigens 40: 90-97 (1992).

• Tilly BC, Winter MC, Ostedgaard LS, O'Riordan C, Smith AE, Welsh MJ. Cyclic AMP-dependent protein kinase activation of cystic fibrosis transmembrane conductance regulator chloride channels in planar lipid bilayers. J. Biol. Chem. 267: 9470-9473 (1992). *

• Torii H, Nakagawa H, Ishibashi Y, Tokunaga K, Juji T. Genetic polymorphisms in the fourth component of complement (C4) and in properdin factor B (BF) in Japanese patients with palmoplantar pustulosis. J. Dermatol. 19: 353-355 (1992).

• Tran-Paterson R, Davin D, Krauss RD, Rado TA, Miller DM. Expression and regulation of the cystic fibrosis gene during rat liver regeneration. Am. J. Physiol. 263: C55-C60 (1992).

• Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buchwald M, Higgins CF. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J. 11: 4291-4303 (1992). *

• Tripathi RC, Kipp MA, Tripathi BJ, Kirschner BS, Borisuth NS, Shevell SK, Ernest JT. Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic. Res. 9: 469-482 (1992).

• Trucco M. To be or not to be Asp 57, that is the question. Diabetes Care 15: 705-715 (1992).

• Tsuchiya K, Nishimura Y, Sasazuki T. Contribution of genetic factors to RA. Nippon Rinsho 50: 438-443 (1992).

• Tsuji H, Murai K, Akagi K, Fujishima M. Familial primary biliary cirrhosis associated with impaired concanavalin A-induced lymphocyte transformation in relatives. Two family studies. Dig. Dis. Sci. 37: 353-360 (1992).

• Tuaillon N, Andre C, Briand JP, Penner E, Muller S. A lipoyl synthetic octadecapeptide of dihydrolipoamide acetyltransferase specifically recognized by anti-M2 autoantibodies in primary biliary cirrhosis. J. Immunol. 148: 445-450 (1992).

• Tucker LE. Primary biliary cirrhosis: current diagnosis and treatment. Gastroenterol. Nurs. 15: 70-76 (1992).

• Ueda N, Nakamura T, Kayahara M, Miyazaki I. Pathogenesis of hepatic atrophy in canine model of hepatolithiasis. Gastroenterol. Jpn. 27: 212-221 (1992).

• Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 16: 1404-1408 (1992).

• Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 355: 830-833 (1992). *

• van Elburg RM, Uil JJ, de Monchy JG, Heymans HS. Intestinal permeability in pediatric gastroenterology. Scand. J. Gastroenterol. Suppl. 194: 19-24 (1992).

• van Endert PM, Lopez MT, Patel SD, Monaco JJ, McDevitt HO. Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes. Proc. Natl. Acad. Sci. U.S.A. 89: 11594-11597 (1992). *

• Van Gossum A. Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review. Acta Gastroenterol. Belg. 55: 462-471 (1992).

• Van Thiel DH, Finkel R, Friedlander L, Gavaler JS, Wright HI, Gordon R. The association of IgA deficiency but not IgG or IgM deficiency with a reduced patient and graft survival following liver transplantation. Transplantation 54: 269-273 (1992).

• Van Tol EA, Verspaget HW, Pena AS, Kraemer CV, Lamers CB. The CD56 adhesion molecule is the major determinant for detecting non-major histocompatibility complex-restricted cytotoxic mononuclear cells from the intestinal lamina propria. Eur. J. Immunol. 22: 23-29 (1992).

• van Tol EA, Verspaget HW, Pena AS, Lamers CB. Normal inflammatory bowel disease mucosa conceals alterations in natural killer cell activity. Scand. J. Gastroenterol. 27: 999-1005 (1992).

• van Waarde WM, van der Heyden AJ. IgA deficiency: clinical and immunological evaluation of 28 patients. Tijdschr. Kindergeneeskd. 60: 31-35 (1992).

• Vehrenkamp DM, Rettke SR, Sittipong R, Ilstrup DM. Association of coagulation tests with blood use during liver transplantation. Nurse Anesth. 3: 166-172 (1992).

• Vierling JM. Immune disorders of the liver and bile duct. Gastroenterol. Clin. North Am. 21: 427-449 (1992).

• Villalon L, Tuchweber B, Yousef IM. Low protein diets potentiate lithocholic acid-induced cholestasis in rats. J. Nutr. 122: 1587-1596 (1992). *

• Vincze A, Patty I, Javor T, Par A. Clinical evidence of hepatoprotection induced by ursodeoxycholic acid. Acta Physiol. Hung. 80: 369-374 (1992).

• Volanakis JE, Zhu ZB, Schaffer FM, Macon KJ, Palermos J, Barger BO, Go R, Campbell RD, Schroeder HW Jr, Cooper MD. Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency. J. Clin. Invest. 89: 1914-1922 (1992). *

• Volk BA, Gerok W. Current insights on the pathogenesis of chronic inflammatory bowel diseases. Schweiz. Rundsch. Med. Prax. 81: 863-865 (1992).

• Volpe R. A perspective on human autoimmune thyroid disease: is there an abnormality of the target cell which predisposes to the disorder? Autoimmunity 13: 3-9 (1992).

• Volta U, Molinaro N, De Franchis R, Forzenigo L, Landoni M, Fratangelo D, Bianchi FB. Correlation between IgA antiendomysial antibodies and subtotal villous atrophy in dermatitis herpetiformis. J. Clin. Gastroenterol. 14: 298-301 (1992).

• Vondracek TG, Seifert CF. Use of ursodiol in a patient with biliary cirrhosis. Clin. Pharm. 11: 672-673 (1992).

• Vu DD, Tuchweber B, Plaa GL, Yousef IM. Do intracellular Ca2+ activity and hepatic glutathione play a role in the pathogenesis of lithocholic acid-induced cholestasis? Toxicol. Lett. 61: 255-264 (1992).

• Wakefield AJ, Fox JD, Sawyerr AM, Taylor JE, Sweenie CH, Smith M, Emery VC, Hudson M, Tedder RS, Pounder RE. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J. Med. Virol. 38: 183-190 (1992).

• Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 102: 810-815 (1992).

• Wang XD, Krinsky NI, Tang GW, Russell RM. Retinoic acid can be produced from excentric cleavage of beta-carotene in human intestinal mucosa. Arch. Biochem. Biophys. 293: 298-304 (1992).

• Wardle TD, Hall L, Turnberg LA. Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut 33: 1644-1651 (1992). *

• Weber P, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F. Microbic superinfection in relapse of inflammatory bowel disease. J. Clin. Gastroenterol. 14: 302-308 (1992).

• Weden M, Glaumann H, Einarsson K. Protracted cholestasis probably induced by oral contraceptive. J. Intern. Med. 231: 561-565 (1992).

• Weiss J, Elsbach P, Shu C, Castillo J, Grinna L, Horwitz A, Theofan G. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Invest. 90: 1122-1130 (1992). *

• Weiss P, Shoenfeld Y. Primary biliary cirrhosis: increasing problem, approaching solution. Isr. J. Med. Sci. 28: 726-728 (1992).

• Wen L, Peakman M, Mieli-Vergani G, Vergani D. Elevation of activated gamma delta T cell receptor bearing T lymphocytes in patients with autoimmune chronic liver disease. Clin. Exp. Immunol. 89: 78-82 (1992). *

• Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann. Intern. Med. 117: 801-806 (1992).

• Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J. Clin. Invest. 90: 2355-2361 (1992). *

• Weyand CM, Xie C, Goronzy JJ. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J. Clin. Invest. 89: 2033-2039 (1992). *

• Wiesner RH, Porayko MK, Dickson ER, Gores GJ, LaRusso NF, Hay JE, Wahlstrom HE, Krom RA. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 16: 1290-1299 (1992).

• Wilkinson MM. Primary sclerosing cholangitis: what are the nursing implications? Gastroenterol. Nurs. 14: 215-218 (1992).

• Willhite CC, Jurek A, Sharma RP, Dawson MI. Structure-affinity relationships of retinoids with embryonic cellular retinoic acid-binding protein. Toxicol. Appl. Pharmacol. 112: 144-153 (1992).

• Williams ML. Ichthyosis: mechanisms of disease. Pediatr. Dermatol. 9: 365-368 (1992).

• Wilson JM, Collins FS. Cystic fibrosis. More from the modellers. Nature 359: 195-196 (1992). *

• Wong KK, Goh KL. Pregnancy in primary biliary cirrhosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 45: 149-151 (1992).

• Wong SS, Holt PJ. Generalized morphoea and primary biliary cirrhosis: a rare association and improvement with oxypentifylline. Clin. Exp. Dermatol. 17: 371-373 (1992).

• Wren BW, Colby SM, Cubberley RR, Pallen MJ. Degenerate PCR primers for the amplification of fragments from genes encoding response regulators from a range of pathogenic bacteria. FEMS Microbiol. Lett. 78: 287-291 (1992).

• Wuarin J, Falvey E, Lavery D, Talbot D, Schmidt E, Ossipow V, Fonjallaz P, Schibler U. The role of the transcriptional activator protein DBP in circadian liver gene expression. J. Cell Sci. Suppl. 16: 123-127 (1992).

• Xia L, Yu T. Study of the relationship between the hepatotoxicity and free radical induced by 1,1,2-trichloroethane and 1,1,1-trichloroethane in rat. Biomed. Environ. Sci. 5: 303-313 (1992).

• Yamamoto AM, Mura C, Morales MG, Bernard O, Krishnamoorthy R, Alvarez F. Study of CYP2D6 gene in children with autoimmune hepatitis and P450 IID6 autoantibodies. Clin. Exp. Immunol. 87: 251-255 (1992). *

• Yamasaki T. Selective IgM deficiency: functional assessment of peripheral blood lymphocytes in vitro. Intern. Med. 31: 866-870 (1992).

• Yeatman N, Sachs J, Bottazzo GF. Autoimmunity - towards the year 2001. Immunol. Today 13: 239-240 (1992).

• Yoshida H, Tomokuni T, Tamura K, Watase K, Matsuwaka R, Matsuda H. A surgical case of thoracic aortic aneurysm due to Takayasu's aortitis associated with ulcerative colitis. Nippon Kyobu Geka Gakkai Zasshi 40: 1135-1139 (1992).

• Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16: 358-364 (1992).

• Zauli D, Baffoni L, Cassani F, Fusconi M, Lenzi M, Ballardini G, Luigi M, Bianchi FB, Schrumpf E. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis, ulcerative colitis, and autoimmune diseases. Gastroenterology 102: 1088-1090 (1992).

• Zetterquist H, Broome U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 33: 942-946 (1992). *

• Zhang L, Weetman AP, Jayne DR, Turner I, Yeaman SJ, Bassendine MF, Oliveira DB. Anti-mitochondrial antibody IgG subclass distribution and affinity in primary biliary cirrhosis. Clin. Exp. Immunol. 88: 56-61 (1992). *

• Zhang Q, Wrana JL, Sodek J. Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a 'silent' second promoter. Eur. J. Biochem. 207: 649-659 (1992).

• Zhang XK, Lehmann J, Hoffmann B, Dawson MI, Cameron J, Graupner G, Hermann T, Tran P, Pfahl M. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 358: 587-591 (1992). *

• Zijlstra FJ, van Dijk AP, Garrelds IM, Ouwendijk RJ, Wilson JH. Species differences in the pattern of eicosanoids produced by inflamed and non-inflamed tissue. Agents Actions Spec. No.: C73-C75 (1992).

• Zijlstra FJ, van Dijk AP, Wilson JH, van Riemsdijk-Overbeeke IC, Vincent JE, Ouwendijk RJ. 15-HETE is the main eicosanoid formed by human colonic mucosa. Agents Actions Spec. No.: C53-C59 (1992).

• Zimmermann H, Reichen J. Ursodeoxycholate has no beneficial effect on liver function or histology in biliary cirrhosis in the rat. J. Hepatol. 16: 355-359 (1992).

• Zimmermann H, Reichen J, Zimmermann A, Sagesser H, Thenisch B, Hoflin F. Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology 103: 579-589 (1992).

• Zurgil N, Bakimer R, Moutsopoulos HM, Tzioufas AG, Youinou P, Isenberg DA, Scheinberg M, Kveder T, Rozman B, Luderschmidt C, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J. Clin. Immunol. 12: 201-209 (1992).

Number of references = 643

www psc-literature.org